<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85279</article-id><article-id pub-id-type="doi">10.7554/eLife.85279</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Cystatin F (<italic>Cst7</italic>) drives sex-dependent changes in microglia in an amyloid-driven model of Alzheimer’s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-299989"><name><surname>Daniels</surname><given-names>Michael JD</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7489-5626</contrib-id><email>mdaniels@ed.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302503"><name><surname>Lefevre</surname><given-names>Lucas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302504"><name><surname>Szymkowiak</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302505"><name><surname>Drake</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-259381"><name><surname>McCulloch</surname><given-names>Laura</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1396-6643</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302506"><name><surname>Tzioras</surname><given-names>Makis</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2660-5943</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302507"><name><surname>Barrington</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-65689"><name><surname>Dando</surname><given-names>Owen R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6269-6408</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-212869"><name><surname>He</surname><given-names>Xin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1753-2591</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302508"><name><surname>Mohammad</surname><given-names>Mehreen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302509"><name><surname>Sasaguri</surname><given-names>Hiroki</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167857"><name><surname>Saito</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302510"><name><surname>Saido</surname><given-names>Takaomi C</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33675"><name><surname>Spires-Jones</surname><given-names>Tara L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2530-0598</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-246008"><name><surname>McColl</surname><given-names>Barry W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0521-9656</contrib-id><email>barry.mccoll@ed.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>UK Dementia Research Institute at The University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>Simons Initiative for the Developing Brain, University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051k3eh31</institution-id><institution>Department of Neurology and Neurological Science, Graduate School of Medicine, Tokyo Medical and Dental University</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04j1n1c04</institution-id><institution>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute</institution></institution-wrap><addr-line><named-content content-type="city">Wako</named-content></addr-line><country>Japan</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04chrp450</institution-id><institution>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University</institution></institution-wrap><addr-line><named-content content-type="city">Nagoya</named-content></addr-line><country>Japan</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wn7wc95</institution-id><institution>Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Nagoya</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Stevens</surname><given-names>Beth</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85279</elocation-id><history><date date-type="received" iso-8601-date="2022-11-30"><day>30</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-11-04"><day>04</day><month>11</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-11-18"><day>18</day><month>11</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.11.18.516922"/></event></pub-history><permissions><copyright-statement>© 2023, Daniels et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Daniels et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85279-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85279-figures-v2.pdf"/><abstract><p>Microglial endolysosomal (dys)function is strongly implicated in neurodegenerative disease. Transcriptomic studies show that a microglial state characterised by a set of genes involved in endolysosomal function is induced in both mouse Alzheimer’s disease (AD) models and human AD brain, and that the emergence of this state is emphasised in females. <italic>Cst7</italic> (encoding cystatin F) is among the most highly upregulated genes in these microglia. However, despite such striking and robust upregulation, the function of <italic>Cst7</italic> in neurodegenerative disease is not understood. Here, we crossed <italic>Cst7<sup>-/-</sup></italic> mice with the <italic>App<sup>NL-G-F</sup></italic> mouse to test the role of <italic>Cst7</italic> in a model of amyloid-driven AD. Surprisingly, we found that <italic>Cst7</italic> plays a sexually dimorphic role regulating microglia in this model. In females, <italic>Cst7<sup>-/-</sup>App<sup>NL-G-F</sup></italic> microglia had greater endolysosomal gene expression, lysosomal burden, and amyloid beta (Aβ) burden <italic>in vivo</italic> and were more phagocytic <italic>in vitro</italic>. However, in males, <italic>Cst7<sup>-/-</sup>App<sup>NL-G-F</sup></italic> microglia were less inflammatory and had a reduction in lysosomal burden but had no change in Aβ burden. Overall, our study reveals functional roles for one of the most commonly upregulated genes in microglia across disease models, and the sex-specific profiles of <italic>Cst7<sup>-/-</sup></italic>-altered microglial disease phenotypes. More broadly, the findings raise important implications for AD including crucial questions on sexual dimorphism in neurodegenerative disease and the interplay between endolysosomal and inflammatory pathways in AD pathology.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>microglia</kwd><kwd>Alzheimer's disease</kwd><kwd>lysosome</kwd><kwd>sexual dimorphism</kwd><kwd>phagocytosis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100017510</institution-id><institution>UK Dementia Research Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Spires-Jones</surname><given-names>Tara L</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001674</institution-id><institution>Leducq Foundation</institution></institution-wrap></funding-source><award-id>Stroke IMPaCT - 19CVD01</award-id><principal-award-recipient><name><surname>McColl</surname><given-names>Barry W</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value><italic>Cst7</italic>, a gene coding for protein cystatin F, is expressed by microglia in neurodegenerative disease models and mediates sex-dependent effects on microglial endolysosomal function and disease pathology.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Alzheimer’s disease (AD) is a chronic neurodegenerative disease characterised pathologically by build-up of protein aggregates such as amyloid beta (Aβ) and hyperphosphorylated tau. AD is also characterised by reactive glial cells, including the emergence of altered microglia. Microglia are the predominant immune cells of the brain parenchyma and play numerous roles in development and homeostasis (<xref ref-type="bibr" rid="bib6">Colonna and Butovsky, 2017</xref>). In recent years, microglia have become heavily implicated in the pathogenesis of AD, in part due to accumulating genetic and epigenetic evidence that single nucleotide polymorphisms leading to altered risk for late-onset AD (LOAD) are enriched in microglial-expressed genes associated with endolysosomal function and lipid handling (<xref ref-type="bibr" rid="bib51">Podleśny-Drabiniok et al., 2020</xref>). This implies that microglia may play a causal role in the disease and supports the theory that microglia may be targeted to treat AD. In addition to genetics, sex is a major risk factor for AD, with women up to twice as likely to be diagnosed than men (<xref ref-type="bibr" rid="bib50">Podcasy and Epperson, 2016</xref>). This sex bias is not entirely due to increased longevity in females, as increased risk remains after adjusting for lifespan, and may be due to interaction effects between sex/gender and genetics (<xref ref-type="bibr" rid="bib14">Gamache et al., 2020</xref>). The mechanisms for this, and possible interplay between microglia and sex are poorly understood.</p><p>Recently, an altered state of microglia has been identified in AD models that arises dependent on AD risk gene <italic>TREM2</italic>. These cells, termed disease-associated microglia (DAM)/microglial neurodegenerative phenotype (MGnD)/activated response microglia (ARM) (<xref ref-type="bibr" rid="bib31">Keren-Shaul et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Krasemann et al., 2017</xref>; <xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>), are characterised by downregulation of microglial ‘homeostatic’ genes <italic>Tmem119</italic> and <italic>P2ry12</italic> and upregulation of genes such as <italic>Apoe</italic>, <italic>Spp1</italic>, <italic>Itgax</italic>, <italic>Clec7a,</italic> and <italic>Cst7</italic>. Notably, the emergence of this subset may be accelerated in female mice compared to male (<xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>). DAM/MGnD/ARM are believed to be highly phagocytic cells due to the enrichment of phagocytic and lipid-handling pathways in their gene sets (<xref ref-type="bibr" rid="bib8">Deczkowska et al., 2018</xref>). However, the precise functions of many of the genes that make up DAM/MGnD/ARM are poorly understood.</p><p><italic>Cst7</italic>, coding for the protein cystatin F (CF), is amongst the most robustly upregulated genes in the DAM/MGnD/ARM signature. <italic>Cst7</italic>/CF expression appears to be driven by amyloid plaques as upregulation at both the RNA and protein level is spatially localised to plaques (<xref ref-type="bibr" rid="bib46">Ofengeim et al., 2017</xref>; <xref ref-type="bibr" rid="bib5">Chen et al., 2020</xref>). CF is atypical in that it is localised to the endolysosomal compartment where it acts as an endogenous inhibitor of cysteine proteases such as cathepsin L and C (<xref ref-type="bibr" rid="bib21">Hamilton et al., 2008</xref>). However, little is understood about the mechanistic role of CF in the context of central nervous system (CNS) disease. Some studies have suggested CF may play a protective role in a demyelination model by inhibiting cathepsin C (<xref ref-type="bibr" rid="bib37">Liang et al., 2016</xref>) or negatively regulating microglial phagocytosis (<xref ref-type="bibr" rid="bib30">Kang et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Popescu et al., 2023</xref>) but the possible disease-modifying role of <italic>Cst7</italic>/CF in amyloid-driven neurodegenerative disease is unknown. Additionally, although there is some evidence that <italic>Cst7</italic> itself is upregulated to a greater extent in female vs. male mice (<xref ref-type="bibr" rid="bib30">Kang et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Guillot-Sestier et al., 2021</xref>), the sex-specific role of <italic>Cst7</italic> in disease has not been investigated.</p><p>Here, we set out to investigate what, if any, disease-modifying role <italic>Cst7</italic>/CF may play in an amyloid-driven AD mouse model in both females and males. We first compiled data from published datasets to show that <italic>Cst7</italic> is indeed robustly and consistently upregulated in microglia across numerous amyloid-driven models of AD. We then deleted <italic>Cst7</italic> in male and female <italic>App<sup>NL-G-F</sup></italic> knock-in mice which showed that <italic>Cst7</italic> drives sex-dependent changes in microglia at transcript, protein, and functional level. <italic>Cst7</italic> deletion in male mice led to downregulation of inflammatory transcripts and reduced lysosomal burden but had no effect on microglial Aβ burden <italic>in vivo</italic> or plaque deposition. However, in females, <italic>Cst7</italic> deletion led to increased expression of endolysosomal genes, increased lysosomal burden, and increased microglial Aβ burden <italic>in vivo</italic>. We further investigated this <italic>in vitro</italic> and showed that this is due to increased phagocytosis rather than impaired degradation. These data bring important insight to the functional role of <italic>Cst7</italic>, a key hallmark gene within the DAM/MGnD/ARM disease microglia signature. They also highlight that pathology-influencing effects are sex-dependent, underlining the interaction between sex and microglial function relevant to neurodegenerative disease.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Cst7</italic>/CF is upregulated in female and male microglia in murine models of AD</title><p><italic>Cst7</italic> is often detected in RNASeq or scRNASeq databases as significantly upregulated in disease models. However, an integrated analysis of <italic>Cst7</italic> expression in disease models stratified by sex is lacking. Therefore, we searched publicly available datasets for <italic>Cst7</italic> expression in microglia in mouse models of AD. We integrated data from six studies in which microglial <italic>Cst7</italic> expression was profiled (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Expression data were restricted to microglia by use of techniques such as fluorescence-activated cell sorting (FACS) (<xref ref-type="bibr" rid="bib47">Orre et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Srinivasan et al., 2020</xref>), immunomagnetic separation (<xref ref-type="bibr" rid="bib19">Guillot-Sestier et al., 2021</xref>), RiboTag translational profiling (<xref ref-type="bibr" rid="bib30">Kang et al., 2018</xref>), or single-cell RNA sequencing (<xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>). We were able to collect data on <italic>Cst7</italic> expression in males <italic>vs.</italic> females in the APP/PS1 (<xref ref-type="bibr" rid="bib19">Guillot-Sestier et al., 2021</xref>) and <italic>App<sup>NL-G-F</sup></italic> model (<xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>). In all models, <italic>Cst7</italic> was dramatically upregulated in microglia in amyloid-driven disease and in models where we were able to compare sexes, <italic>Cst7</italic> appeared marginally more highly expressed in female disease brains than in male. This is consistent with literature suggesting the DAM/ARM/MGnD microglial subset is accelerated in female mice (<xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>). We further investigated sexual dimorphism in microglial states by sub-setting ARMs from Sala-Frigerio et al. and discovered, alongside sex-chromosome genes, endolysosomal genes such as <italic>Spp1</italic> and <italic>Gpnmb</italic> amongst <italic>Cst7</italic> as marginally more expressed in female ARMs <italic>vs.</italic> male ARMs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). To investigate cell-specific expression of <italic>Cst7</italic>, we mined sequencing databases and found <italic>Cst7</italic> is expressed almost exclusively in disease-derived microglial clusters with some minimal expression in homeostatic microglia and negligible expression in other CNS or immune cell subtypes (<xref ref-type="bibr" rid="bib71">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Van Hove et al., 2019</xref>; <xref ref-type="bibr" rid="bib70">Zeng et al., 2023</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–D</xref>). Finally, we investigated the expression of <italic>Cst7</italic> in intact tissue by conducting <italic>in situ</italic> hybridisation for <italic>Cst7</italic> with markers for IBA1 and Aβ plaques for localisation. We found that <italic>Cst7</italic> was dramatically upregulated in disease where expression decorated plaques in <italic>App<sup>NL-G-F</sup></italic> brains (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Furthermore, expression was significantly enriched around plaques (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>) and almost exclusively localised to IBA1+ cells surrounding plaques (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). Together, these data validate <italic>Cst7</italic> as a key marker gene of disease-induced reactive microglia, notably of the DAM/MGnD/ARM state, across cerebral amyloidosis models in both sexes, and suggest that its disease-induced upregulation is related temporally and spatially to Aβ plaque pathology.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Cst7</italic>/cystatin F is upregulated in microglia in murine models of Alzheimer’s disease (AD).</title><p>(<bold>A</bold>) Analysis of publicly available microglial RNASeq databases for <italic>Cst7</italic> expression in amyloid-driven models. Background-matched control (grey) or relevant disease model (blue). (<bold>B</bold>) Brightfield slide-scanned images of wild-type (left) and <italic>App<sup>NL-G-F</sup></italic> (right) sagittal brain sections stained by <italic>in situ</italic> hybridisation for <italic>Cst7</italic> (red). (<bold>C</bold>) Example image from <italic>Cst7</italic> fluorescence <italic>in situ</italic> hybridisation (FISH) experiment stained with IBA1 (green), 6E10 (magenta), and <italic>Cst7</italic> (cyan). (<bold>D</bold>) Quantification of (<bold>C</bold>) showing % <italic>Cst7</italic>+ area in areas within 25 µm (blue) of 6E10+ plaques or outside (grey). (<bold>E</bold>) Hi-mag confocal microscopy maximum intensity projection showing co-localisation of <italic>Cst7</italic> with IBA1 around plaques. (<bold>F</bold>) Quantification of (<bold>E</bold>) showing % <italic>Cst7</italic> overlap with IBA1. n=3–7. **p&lt;0.01, ***p&lt;0.001 by unpaired t-test or two-way ANOVA with Tukey’s multiple comparisons post hoc test. #p&lt;0.05 by paired t-test. Scale bars are 20 µm.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data associated with <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title><p>(<bold>D</bold>) Quantification of (<bold>C</bold>) showing % <italic>Cst7</italic>+ area in areas within 25 µm of 6E10+ plaques or outside. (<bold>F</bold>) Quantification of (<bold>E</bold>) showing % <italic>Cst7</italic> overlap with IBA1.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85279-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Investigating expression of <italic>Cst7</italic>.</title><p>(<bold>A</bold>) Sub-set analysis of activated response microglia (ARM) cluster from Sala-Frigerio et al. expression of genes in females <italic>vs.</italic> males. Selected genes annotated. (<bold>B–D</bold>) <italic>Cst7</italic> expression from published datasets. Data plotted using web tools on <ext-link ext-link-type="uri" xlink:href="https://www.brainrnaseq.org/">https://www.brainrnaseq.org/</ext-link> (<bold>B</bold>), <ext-link ext-link-type="uri" xlink:href="https://singlecell.broadinstitute.org">https://singlecell.broadinstitute.org</ext-link> (<bold>C</bold>), and <ext-link ext-link-type="uri" xlink:href="https://www.brainimmuneatlas.org/">https://www.brainimmuneatlas.org/</ext-link> (<bold>D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>Cst7</italic> deletion leads to sex-dependent transcriptomic changes in microglia in the <italic>App<sup>NL-G-F</sup></italic> model of amyloid-driven AD</title><p>As <italic>Cst7</italic> is so robustly upregulated in microglia in amyloid-driven disease and some studies suggest this to be greater in female mice, we next aimed to investigate whether <italic>Cst7</italic>/CF plays a role in regulating microglia in disease and whether this regulation could be sex-dependent. Therefore, we crossed <italic>Cst7<sup>-/-</sup></italic> mice with the <italic>App<sup>NL-G-F</sup></italic> model of amyloid-driven AD (<xref ref-type="bibr" rid="bib54">Saito et al., 2014</xref>) to generate background-matched non-disease (<italic>App<sup>Wt/Wt</sup>Cst7<sup>+/+</sup></italic>), disease (<italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic>) and disease knockout (<italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic>) mice. As <italic>Cst7</italic> expression is limited to the myeloid compartment in the brain (<xref ref-type="bibr" rid="bib71">Zhang et al., 2014</xref>), this study primarily tests the role of microglial/border-associated macrophages in amyloid-driven disease. We first investigated the role of <italic>Cst7</italic>/CF in regulating the microglial response in disease by unbiased analysis of the microglial transcriptome. Mice were aged to 12 months to drive Aβ plaque burden and a DAM/ARM microglial profile that includes marked upregulation of <italic>Cst7</italic> before microglia were isolated from hemi-brains by FACS (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Microglia were defined by FSC/SSC profile, singlet, live, CD11b+, Ly6C-, CD45+ (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and sorted along with phenotypic markers P2Y12, MHCII, and CD11c (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) before RNA purification, sequencing, and analysis using DESeq2 (<xref ref-type="bibr" rid="bib40">Love et al., 2014</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Cst7</italic> deletion leads to sex-dependent transcriptomic changes in microglia in the <italic>App<sup>NL-G-F</sup></italic> model of amyloid-driven Alzheimer’s disease (AD).</title><p>(<bold>A</bold>) Study design schematic. (<bold>B</bold>) Differentially expressed genes (DEGs) between wild-type and <italic>App<sup>NL-G-F</sup></italic> microglia in male and female mice. (<bold>C</bold>) Volcano plot of RNASeq from wild-type <italic>vs. App<sup>NL-G-F</sup></italic> female microglia. Points in red are significantly upregulated in disease. Points in blue are significantly downregulated. Selected genes are annotated. (<bold>D</bold>) Volcano plot of RNASeq from wild-type <italic>vs. App<sup>NL-G-F</sup>Cst7</italic><sup>+/+</sup> male microglia. (<bold>E</bold>) Volcano plot of RNASeq from female <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>+/+</sup> <italic>vs. App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> microglia. Points in red are significantly upregulated in <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup>. Points in blue are significantly downregulated. Selected genes are annotated. (<bold>F</bold>) Selected GO:BP (Gene Ontology:biological process) terms that are significantly enriched in the upregulated genes from (<bold>E</bold>) and corresponding significance p-value. (<bold>G</bold>) Volcano plot of RNASeq from male <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup> vs. App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> microglia. (<bold>H</bold>) Selected GO:BP terms that are significantly enriched in the upregulated genes from (<bold>G</bold>) and corresponding significance p-value. (I and J) Example gene expression (fpkm) from RNASeq of microglia isolated from male and female wild-type, <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7<sup>+/+</sup>,</italic> and <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7</italic><sup>-/-</sup> mice. Selected genes are <italic>Lilrb4</italic> (<bold>I</bold>) and <italic>Cxcl2</italic> (<bold>J</bold>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data associated with <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title><p>(I and J) Example gene expression (fpkm) from RNASeq of microglia isolated from male and female wild-type, <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7<sup>+/+</sup>,</italic> and <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7</italic><sup>-/-</sup> mice. Selected genes are <italic>Lilrb4</italic> (<bold>I</bold>) and <italic>Cxcl2</italic> (<bold>J</bold>).</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85279-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Differentially expressed genes (DEGs) between male and female App<sup>NL-G-F</sup> and <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7</italic><sup><italic>-/-</italic></sup> mice (selected genes in bold).</title></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-85279-fig2-data2-v2.docx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Gating strategy for microglia fluorescence-activated cell sorting (FACS).</title><p>Microglia/BAMs were defined as single cells, Zombie NIR- live cells, CD11b+CD45+ myeloid cells, Ly6C- microglia/BAMs. Phenotypic markers MHCII and CD11c were also tested. All gates were set using fluorescence minus one (FMO) controls.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Gene expression from RNASeq data.</title><p>(<bold>A</bold>) Example expression (fpkm) of <italic>Cst7</italic> from RNASeq of microglia isolated from male and female wild-type, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> mice. (<bold>B</bold>) Venn diagram showing differentially expressed genes (DEGs) in <italic>App<sup>NL-G-F</sup></italic> microglia that are male only (left), shared between male and female (middle), or female only (right). (<bold>C</bold>) Venn diagram showing DEGs in <italic>Cst7<sup>-/-</sup></italic> microglia that are male only (left), shared between male and female (middle), or female only (right). (<bold>D</bold>) DEGs in male <italic>vs.</italic> female <italic>App<sup>NL-G-F</sup></italic> or <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> mice. (<bold>E</bold>) Example image from <italic>Lilrb4a</italic> fluorescence <italic>in situ</italic> hybridisation (FISH) experiment stained with IBA1 (green), 6E10 (magenta), and <italic>Lilrb4a</italic> (cyan) showing co-localisation of <italic>Lilrb4a</italic> with IBA1 around plaques. (<bold>F</bold>) Quantification of (<bold>E</bold>) showing <italic>Lilrb4a</italic> expression in IBA1+ cells in male and female <italic>App<sup>NL-G-F</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> brains. n=6. *p&lt;0.05 by two-way ANOVA with Sidak’s multiple comparisons post hoc test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Gene expression from RNASeq data compared to qPCR from naïve (non-diseased) mice.</title><p>(<bold>A</bold>) Expression (fpkm) of <italic>Lilrb4a</italic> and <italic>Il1b</italic> from RNASeq of wild-type (grey), <italic>App<sup>NL-G-F</sup></italic> (blue), or <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) microglia from male and female mice. (<bold>B</bold>) Relative expression (ddCt <italic>vs.</italic> mean of male wild-type) of <italic>Lilrb4a</italic> and <italic>Il1b</italic> from naïve (non-diseased) wild-type (grey) and <italic>Cst7<sup>-/-</sup></italic> (red) microglia. n=3–4. Analysed by DESeq2 (<bold>A</bold>) or by two-way ANOVA with Sidak’s multiple comparisons post hoc test (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig2-figsupp3-v2.tif"/></fig></fig-group><p>We first assessed disease-induced microglial changes by comparing <italic>App<sup>Wt/Wt</sup>Cst7<sup>+/+</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> microglia in male and female mice. <italic>App<sup>NL-G-F</sup></italic> knock-in led to numerous changes in gene transcription with 2022 genes upregulated and 1849 downregulated in males and 2053 upregulated and 1857 downregulated in females (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Differentially regulated genes were mostly shared between males and females but we did observe uniquely regulated genes between sexes (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). As expected, upregulated genes included DAM/ARM genes such as <italic>Clec7a</italic>, <italic>Spp1</italic>, <italic>Itgax,</italic> and <italic>Csf1,</italic> whilst downregulated genes included microglial ‘homeostatic’ genes <italic>P2ry12</italic>, <italic>Tmem119,</italic> and <italic>Gpr34</italic> in both sexes (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). <italic>Cst7</italic> was among the top 10 most highly upregulated genes in males and females. Interestingly, although there were relatively few differentially expressed genes (DEGs) between male and female mice in the <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> group (<xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>), these genes did include DAM/ARM genes such as <italic>Gpnmb</italic>, <italic>Spp1,</italic> and <italic>Ctse</italic>. This is consistent with the observation that the DAM/ARM profile is accelerated in females compared to males (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>).</p><p>Having confirmed the upregulation of the <italic>Cst7</italic> and the DAM/ARM profile in this model, we next tested the role of <italic>Cst7</italic> in disease by comparing differential expression between the <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> groups in both sexes. Importantly, <italic>Cst7</italic> itself was the most DEG in both sexes, confirming successful deletion (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). <italic>Cst7</italic> deletion led to significant changes in microglial transcriptome. In females, <italic>Cst7</italic> knockout led to upregulation of 15 genes and downregulation of 2 genes (including <italic>Cst7</italic>) (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Despite the modest number of DEGs, we observed that many of the upregulated genes appeared to be involved in endolysosomal-related processes such as protein trafficking to organelles (<italic>Sort1</italic>, <italic>Sec16a</italic>) and antigen presentation (<italic>Lilrb4a</italic>, <italic>Igkc</italic>). Enrichment analyses revealed that female <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> microglia were significantly enriched in GO:BP (Gene Ontology: biological process) terms such as ‘plasma membrane to endosome transport’, ‘aggrephagy’, and ‘phagocytosis’ against their <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> counterparts (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><p>Next, we tested whether <italic>Cst7</italic> knockout led to the same effect in males as in females. Surprisingly, we observed that male <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> microglia exhibited markedly different transcriptome compared to <italic>App<sup>NL-G-F</sup></italic> with upregulation of 8 genes and downregulation of 51 genes (including <italic>Cst7</italic>) (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). In contrast to females, downregulated genes in males were dominated by classical proinflammatory mediators such as <italic>Il1b</italic>, <italic>Il1a</italic>, <italic>Tnf,</italic> and <italic>Cxcl2</italic> and enrichment analyses revealed downregulation of GO:BP terms such as ‘cellular response to lipopolysaccharide’, inflammatory response’, and ‘NF-kappaB signaling’ (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). There was very little overlap between <italic>Cst7</italic>-regulated genes in males and females with only two genes shared including <italic>Cst7</italic> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>). Notably, many disease-induced genes followed an intriguing pattern of being suppressed in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> in males but potentiated in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> in females. Examples of this are immunoglobulin receptor gene <italic>Lilrb4a</italic> and inflammatory gene <italic>Cxcl2</italic> (<xref ref-type="fig" rid="fig2">Figure 2I and J</xref>). Interestingly, <italic>Cst7</italic> also appeared to drive a sex-genotype interaction effect. We determined male <italic>vs.</italic> female DEGs in <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and their <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> counterparts. In <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> microglia, there were 33 DEGs between male vs. female approximately evenly split between transcripts enriched in males <italic>vs.</italic> those enriched in females, whereas in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> we observed 240 DEGs dominated by those enriched in females (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). These transcripts included inflammatory genes such as <italic>Il1b</italic>, <italic>Tnf,</italic> and <italic>Cxcl2</italic>.</p><p>Finally, we sought to validate our findings through complimentary methods and confirm the gene changes we observe are microglia-expressed. We used fluorescence <italic>in situ</italic> hybridisation (FISH) coupled with immunostaining to measure expression of <italic>Lilrb4a</italic> in non-processed brain tissue. We confirmed expression of <italic>Lilrb4a</italic> in microglia specifically around plaques and validated our RNASeq data showing an identical expression pattern to that observed previously with increased expression of microglial <italic>Lilrb4a</italic> in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> in females but not in males (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 3E and F</xref>). We also assessed expression of key hit genes <italic>Lilrb4a</italic> and <italic>Il1b</italic> by performing qPCR in microglia isolated from non-diseased wild-type vs <italic>Cst7<sup>-/-</sup></italic> mice to confirm disease-specific regulation. Indeed, we did not see the same pattern as described in RNASeq with upregulation in disease and further upregulation in <italic>Cst7<sup>-/-</sup></italic> in females (<italic>Lilrb4a</italic>) or downregulation in <italic>Cst7<sup>-/-</sup></italic> males (<italic>Il1b</italic>) (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). In fact, there were no significant differences between groups (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>).</p><p>Together, these data show that <italic>Cst7</italic> drives sex-dependent effects on microglial transcriptome in an amyloid-driven mouse model of AD. <italic>Cst7</italic> knockout led to a disease-dependent upregulation of a small set of endolysosomal-enriched genes in female microglia but a striking downregulation of inflammatory genes in male microglia. The number of DEGs between <italic>App<sup>NL-G-F</sup></italic> males and females was markedly greater in the <italic>Cst7<sup>-/-</sup></italic> state, implying a sex-genotype interaction effect, that is, the impact of <italic>Cst7</italic> deficiency on microglial phenotype in <italic>App<sup>NL-G-</sup></italic><sup>F</sup>-driven disease differs quantitatively and qualitatively (e.g. in endolysosomal and inflammatory pathways) according to sex.</p></sec><sec id="s2-3"><title><italic>Cst7</italic> deletion leads to region and sex-dependent changes in lysosomes in <italic>App</italic><sup><italic>NL-G-F</italic></sup> mice</title><p>Following our investigation into the <italic>Cst7</italic>-dependent effects on microglia at the transcriptome level, we next sought to study changes at the protein level with spatial resolution. This allowed us to investigate brain region-dependent effects. We took sagittal brain sections from 12-month male and female <italic>App<sup>Wt/Wt</sup>Cst7<sup>+/+</sup></italic>, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> mice and immunostained for IBA1 to visualise microglia/macrophages, anti-Aβ clone 6E10 to visualise Aβ, and, as both previous literature and our RNASeq data in <xref ref-type="fig" rid="fig2">Figure 2</xref> implicated lysosomes in <italic>Cst7</italic> function, LAMP2 to visualise lysosomes. We assessed three brain regions: cortex, whole hippocampus, and the dorsal subiculum (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), to investigate the effects of disease and <italic>Cst7</italic> knockout on microglial burden and lysosomal activation. As expected, knock-in of the <italic>App<sup>NL-G-F</sup></italic> construct led to marked build-up of 6E10+ Aβ plaques, an increase in IBA1+ microglial burden around these plaques, and upregulation of LAMP2 in microglia predominantly in plaque-associated microglia in both males and females (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). LAMP2 predominantly co-localised with IBA1, suggesting that expression is predominant in mononuclear phagocytes rather than neuronal cells or macroglia. Next, we compared <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup> vs. App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> male and female mice. We observed a trend towards increased IBA1+ microglial burden in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> mice in all brain regions, statistically significant in the subiculum (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>), more evidently in male mice. Importantly, this was not only due to an increase in Aβ plaque load (which correlated with microglial burden) as images were quantified in areas of even plaque coverage (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B–D</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Cst7</italic> deletion leads to region and sex-dependent changes in lysosomes in <italic>App<sup>NL-G-F</sup></italic> mice.</title><p>(<bold>A</bold>) Example images from male and female wild-type and <italic>App<sup>NL-G-F</sup></italic> cortex stained with IBA1 (green), 6E10 (magenta), and LAMP2 (cyan). (<bold>B–D</bold>) IBA1 % coverage from images taken of wild-type, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> brains in cortex (<bold>B</bold>), hippocampus (<bold>C</bold>), and dorsal subiculum (<bold>D</bold>). (<bold>E</bold>) Example images from <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7</italic><sup>-/-</sup> subicula in male and female mice. Top panel shows LAMP2 (cyan) and bottom panel shows IBA1 (green), 6E10 (magenta), and LAMP2 (cyan) merge. Scale bars are 50 μm. (<bold>F–H</bold>) Ratio of IBA1/LAMP2 double positive staining <italic>vs.</italic> IBA1 total staining in the cortex (<bold>F</bold>), hippocampus (<bold>G</bold>), and dorsal subiculum (<bold>H</bold>) of wild-type, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> mice. (I and J) Example images from the cortex (<bold>I</bold>) and subiculum (<bold>J</bold>) of an <italic>App<sup>NL-G-F</sup></italic> mouse stained with 6E10 (magenta) and MeX04 (white). (<bold>K</bold>) Ratio of MeX04 total staining <italic>vs.</italic> 6E10 total staining in cortex (blue), hippocampus (red), and subiculum (green) of male and female <italic>App<sup>NL-G-F</sup></italic> mice. Scale bars are 50 μm. Data points are average from 2 fields of view/mouse (1 for subiculum) and bars are plotted as mean + SEM. n=5–12. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by two-way ANOVA with Tukey’s multiple comparisons post hoc test.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data associated with <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title><p>(<bold>B–D</bold>) IBA1 % coverage from images taken of wild-type, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> brains in cortex (<bold>B</bold>), hippocampus (<bold>C</bold>), and dorsal subiculum (<bold>D</bold>). (<bold>F–H</bold>) Ratio of IBA1/LAMP2 double positive staining vs. IBA1 total staining in the cortex (<bold>F</bold>), hippocampus (<bold>G</bold>), and dorsal subiculum (<bold>H</bold>) of wild-type, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> mice. (<bold>K</bold>) Ratio of MeX04 total staining <italic>vs.</italic> 6E10 total staining in cortex (blue), hippocampus (red), and subiculum (green) of male and female <italic>App<sup>NL-G-F</sup></italic> mice.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85279-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Immunohistochemistry supplementary information.</title><p>(<bold>A</bold>) Whole slide scan of an <italic>App<sup>NL-G-F</sup></italic> brain stained with 6E10 (red) and MeX04 (white) to illustrate regions of interest taken for analysis. Example regions are cortex (blue square), hippocampus (red square), and subiculum (green square). (<bold>B–D</bold>) % 6E10 burden in cortex (<bold>B</bold>), hippocampus (<bold>C</bold>), and subiculum (<bold>D</bold>) of male and female wild-type, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> mice. (<bold>E</bold>) % LAMP2 burden <italic>vs.</italic> % IBA1 burden scatter plot from all mice in study with linear regression. n=5–12. ***p&lt;0.001 by two-way ANOVA with Tukey’s multiple comparisons post hoc test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To investigate the effect of <italic>Cst7</italic> deletion on lysosomal activity, we quantified LAMP2 immunostaining and normalised to IBA1 as these markers are highly correlated (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>) and we wanted to remove the confounding factor of a greater IBA1 burden in <italic>Cst7</italic> knockout mice (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). Strikingly, we found in the subiculum that microglial-normalised LAMP2 staining followed the same pattern as many of the genes identified by microglia RNASeq with reduced expression in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> males but increased expression in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> females (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, quantification in <xref ref-type="fig" rid="fig3">Figure 3H</xref>). A similar pattern was observed in the cortex and hippocampus but without a significant change in females (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>). We hypothesised that the reason for this region-dependent effect may be due to differences in plaque structure. Aβ plaques typically comprise a β-sheet-containing dense core and a more diffuse outer ring (<xref ref-type="bibr" rid="bib10">DeTure and Dickson, 2019</xref>). We utilised Congo Red derivative methoxy-X04 (MeX04), which binds selectively to fibrillar β-sheet-rich structures such as the dense cores of amyloid plaques (<xref ref-type="bibr" rid="bib10">DeTure and Dickson, 2019</xref>), compared to anti-Aβ antibody 6E10, which will bind both dense cores and diffuse outers to study plaque composition in different brain regions of <italic>App<sup>NL-G-F</sup></italic> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). MeX04 was injected intraperitoneally 2.5 hr before mice were sacrificed and brains taken for histology. We found that Aβ plaques had a far greater MeX04:6E10 ratio in the subiculum compared to other brain regions (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>, quantified in <xref ref-type="fig" rid="fig3">Figure 3K</xref>), most likely caused by earlier Aβ accumulation in this region (<xref ref-type="bibr" rid="bib53">Rönnbäck et al., 2011</xref>; <xref ref-type="bibr" rid="bib13">Gail Canter et al., 2019</xref>) that may be dependent on a subpopulation of microglia (<xref ref-type="bibr" rid="bib57">Spangenberg et al., 2019</xref>). This implies that the sex-dependent effects of <italic>Cst7</italic> deletion on microglial lysosomes may be driven by plaque composition/structure, with regions dominated by dense core plaques (indicating further ‘disease progression’) showing greater effect of <italic>Cst7</italic> deletion.</p></sec><sec id="s2-4"><title><italic>Cst7</italic> regulates microglial Aβ burden in female <italic>App</italic><sup><italic>NL-G-F</italic></sup> mice</title><p>After discovering that <italic>Cst7</italic> deletion leads to sex-dependent changes in microglia at both the transcriptome and protein level indicative of an altered endolysosomal system, we next further investigated potential functional changes in these altered microglia. A major function of microglia in the context of AD is uptake of Aβ into lysosomes (<xref ref-type="bibr" rid="bib18">Grubman et al., 2021</xref>). To study this, we utilised MeX04 injection as described previously to label Aβ-containing microglia in the brain. First, we validated that intraperitoneal injection of MeX04 2.5 hr before microglial isolation by FACS can detect Aβ-containing microglia. Wild-type and <italic>App<sup>NL-G-F</sup></italic> mice were aged to 12 months and injected with either MeX04 or vehicle before microglial isolation by FACS as previously but with additional detection of MeX04 in the DAPI channel. As expected, wild-type+MeX04 and <italic>App<sup>NL-G-F</sup></italic>+vehicle mice displayed a background MeX04 signal that was shifted only in the <italic>App<sup>NL-G-F</sup></italic>+MeX04 group (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p>After validating our approach, we next investigated the role of <italic>Cst7</italic> on microglial Aβ burden (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Consistent with our RNASeq and histology data suggesting increased lysosomal capacity specifically in female <italic>App<sup>NL-G-F</sup></italic> mice following deletion of <italic>Cst7</italic>, we observed a greater Aβ burden in female <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> microglia compared to <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> counterparts measured by both % Aβ-positive microglia (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) and mean fluorescence intensity of MeX04 on microglia (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Interestingly, despite a reduced expression of lysosomal membrane marker LAMP2 in male <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> mice compared to <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> counterparts (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>), we observed no difference in microglial Aβ burden (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This may be due to the counteracting effect of a reduction of inflammatory genes such as <italic>Il1b</italic> and <italic>Nlrp3</italic> (<xref ref-type="fig" rid="fig2">Figure 2G</xref>) which have been shown to impair phagocytosis (<xref ref-type="bibr" rid="bib23">Heneka et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Tejera et al., 2019</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>Cst7</italic> regulates microglial Aβ burden in female <italic>App<sup>NL-G-F</sup></italic> mice.</title><p>(<bold>A</bold>) Study design schematic. (<bold>B</bold>) % MeX04+ microglia of total microglia in male and female wild-type (grey), <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue), and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) brains. (<bold>C</bold>) Median fluorescence intensity (MFI) of MeX04 in microglia. (<bold>D</bold>) MFI of CD45 on microglia. (<bold>E</bold>) % CD11c+ microglia of total microglia. (<bold>F</bold>) % MHC-II+ microglia of total microglia. (<bold>G</bold>) MFI of P2Y12 on microglia. Bars are plotted as mean + SEM. n=5–12. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by two-way ANOVA with Sidak’s multiple comparisons post hoc test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data associated with <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>(<bold>B</bold>) % MeX04+ microglia of total microglia in male and female wild-type (grey), <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue), and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) brains. (<bold>C</bold>) Median fluorescence intensity (MFI) of MeX04 in microglia. (<bold>D</bold>) MFI of CD45 on microglia. (<bold>E</bold>) % CD11c+ microglia of total microglia. (<bold>F</bold>) % MHC-II+ microglia of total microglia. (<bold>G</bold>) MFI of P2Y12 on microglia.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85279-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Validating MeX04 to measure Aβ-containing microglia.</title><p>Fluorescence-activated cell sorting (FACS) plots of microglia gated by MeX04 and SSC-A. Plots show data from a wild-type mouse injected with MeX04 (left), an aged <italic>App</italic><sup><italic>NL-G-F</italic></sup> mouse injected with vehicle (middle), and an aged <italic>App<sup>NL-G-F</sup></italic> mouse injected with MeX04 (right).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig4-figsupp1-v2.tif"/></fig></fig-group><p>The benefit of using a FACS-based approach to investigating microglial Aβ burden is the opportunity to include surface phenotypic markers to assess microglial reactivity. We assessed expression of CD45, a broad but sensitive marker of activation intensity within microglia; P2Y12, a microglial homeostatic marker; CD11c, a marker shown to be upregulated in disease/damage-associated microglia (<xref ref-type="bibr" rid="bib31">Keren-Shaul et al., 2017</xref>) and MHCII, a marker of antigen presentation, a process which is also dependent on peptide processing through the endolysosomal system (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). <italic>App<sup>NL-G-F</sup></italic> microglia had increased expression of CD45, CD11c, and MHCII compared to wild-type counterparts (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>). We did not detect a reduction in P2Y12 expression (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). <italic>Cst7</italic> deletion did not lead to any significant differences in detection of these markers, although we did note a trend towards increased MHCII+ microglia only in female mice, perhaps consistent with elevated endolysosomal activity and our RNASeq data suggesting an increase in antigen presentation pathway genes specifically in this group.</p></sec><sec id="s2-5"><title><italic>Cst7</italic> negatively regulates phagocytosis in microglia from female <italic>App</italic><sup><italic>NL-G-F</italic></sup> mice</title><p>Our current data suggest that <italic>Cst7</italic> plays a sex-dependent regulatory role on microglia leading to increased endolysosomal gene pathways, region-dependent lysosomal activity, and Aβ burden in female <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> microglia. However, <italic>in vivo</italic> it is challenging to ascertain whether the increase in microglial Aβ is due to an increased uptake or to an impaired degradation. To test this, we conducted <italic>in vitro</italic> assays on <italic>Cst7<sup>+/+</sup></italic> and <italic>Cst7<sup>-/-</sup></italic> microglia to examine phagolysosomal and related functions. Initially, we examined microglia from young adult <italic>Cst7<sup>+/+</sup></italic> and <italic>Cst7<sup>-/-</sup></italic> background-matched mice to understand any baseline differences in the absence of a disease exposure. Unlike constitutively highly expressed microglial genes such as <italic>Trem2</italic> where knockout leads to dramatic alterations in <italic>in vitro</italic> phenotype (<xref ref-type="bibr" rid="bib60">Takahashi et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Hsieh et al., 2009</xref>; <xref ref-type="bibr" rid="bib33">Kleinberger et al., 2014</xref>; <xref ref-type="bibr" rid="bib69">Yeh et al., 2016</xref>), <italic>Cst7</italic> is expressed at very low levels basally (<xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Therefore, we reasoned that <italic>Cst7</italic> deletion would have limited impact on microglial phenotype at baseline where <italic>Cst7</italic> is not highly expressed. Comparing <italic>Cst7<sup>+/+</sup></italic> and <italic>Cst7<sup>-/-</sup></italic> microglia, we observed no significant difference in uptake of Aβ oligomers, human AD synaptoneurosomes, <italic>Staphylococcus aureus</italic> bioparticles, or myelin debris (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–D</xref>); degradation of Aβ (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>); or lysosomal hydrolysis measured by the ability to cleave the quencher molecule from DQ-BSA (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>); transcriptional response to LPS, IL-4, or apoptotic neurons (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G–I</xref>); cytokine secretion in response to LPS or IL-4 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>) or NLRP3 inflammasome activation by silica particles (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1J and K</xref>). We also addressed the possibility of compensation in adult knockout mice by using siRNA to knock down <italic>Cst7</italic> in the BV-2 microglia cell line and found that, despite 70% reduction in gene expression (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref>), <italic>Cst7</italic> knockdown had no effect on IL-6 secretion (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3B</xref>) or transcriptional changes response to LPS or IL-4 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3C–E</xref>).</p><p>Therefore, in order to investigate CF function <italic>in vitro</italic> in the context of the disease-associated marked induction of microglial <italic>Cst7</italic> expression (see above), we developed a model system using primary microglia isolated from 12-month <italic>App<sup>NL-G-F</sup></italic> mice and cultured them for 3 days <italic>in vitro</italic> (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We found that microglia isolated from <italic>App<sup>NL-G-F</sup></italic> mice then cultured for 3 days express 20-fold more <italic>Cst7</italic> than from age-matched wild-type counterparts (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). We also found that these <italic>App<sup>NL-G-F</sup></italic> microglia express two-fold less <italic>Tmem119</italic>, an established microglial homeostatic gene, than wild-type cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). These data suggest that, despite removal from a disease brain and subsequent culture <italic>in vitro</italic>, 12-month-old <italic>App<sup>NL-G-F</sup></italic> microglia retain key elements of their <italic>in vivo</italic> disease transcriptional identity.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>Cst7</italic> negatively regulates phagocytosis in microglia from female <italic>App<sup>NL-G-F</sup></italic> mice.</title><p>(<bold>A</bold>) Study design schematic. (<bold>B–C</bold>) qPCR data for <italic>Cst7</italic> (<bold>B</bold>) and <italic>Tmem119</italic> (<bold>C</bold>) RNA expression from female wild-type and <italic>App<sup>NL-G-F</sup></italic> microglia isolated by CD11b beads and cultured for 3 days <italic>in vitro</italic>. Bars represent mean fold change calculated by ΔΔCt. n=4. *p&lt;0.05, ***p&lt;0.001 by two-way t-test. (<bold>D–E</bold>) Cathepsin L (<bold>D</bold>) and C (<bold>E</bold>) activity from female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) microglia measured by probe-based assay. Bars represent mean relative fluorescence units (RFU) + SEM. n=4–5. (<bold>F</bold>) Example images from myelin phagocytosis assays with female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) microglia taken immediately before (t=0) and 2 hr 45 min after (t=2 hr 45 min) addition of pHrodo-tagged myelin. (<bold>G</bold>) Quantification of (<bold>F</bold>). Data shown are mean RFU (calculated as total integrated intensity of pHrodo Red normalised to cell confluence) ± SEM. n=4. *p&lt;0.05 calculated by unpaired t-test on area under curve (AUC) of data.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data associated with <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p>(<bold>B–C</bold>) qPCR data for <italic>Cst7</italic> (<bold>B</bold>) and <italic>Tmem119</italic> (<bold>C</bold>) RNA expression from female wild-type and <italic>App<sup>NL-G-F</sup></italic> microglia isolated by CD11b beads and cultured for 3 days <italic>in vitro</italic>. (<bold>D–E</bold>) Cathepsin L (<bold>D</bold>) and C (<bold>E</bold>) activity from female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) microglia measured by probe-based assay. (<bold>G</bold>) Quantification of myelin phagocytosis assays with female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> microglia taken immediately before (t=0) and 2 hr 45 min after (t=2 hr 45 min) addition of pHrodo-tagged myelin.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85279-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Investigating Cst7 knockout <italic>in vitro</italic>.</title><p>(<bold>A–D</bold>) Uptake of various tagged substrates from male (solid lines/symbols) and female (dotted lines/symbols) wild-type (black) and <italic>Cst7</italic><sup>-/-</sup> (red) microglia. Substrates tested were HiLyte647-tagged Aβ<sub>1-42</sub>(A), pHrodo-tagged myelin (<bold>B</bold>), pHrodo-tagged <italic>S. aureus</italic> (<bold>C</bold>), and pHrodo-tagged human Alzheimer’s disease (AD) synaptoneurosomes (<bold>D</bold>). (<bold>E</bold>) Uptake and degradation of HiLyte647-tagged Aβ<sub>1-42</sub> from male (solid lines/symbols) and female (dotted lines/symbols) wild-type (black) and <italic>Cst7</italic><sup>-/-</sup> (red) microglia and microglia treated with pan-cathepsin inhibitor K777 (10 µM, blue lines/symbols). (<bold>F</bold>) Lysosomal proteolysis measured by de-quenching of DQ-BSA from male (solid lines/symbols) and female (dotted lines/symbols) wild-type (black) and <italic>Cst7</italic><sup>-/-</sup> (red) microglia and microglia treated with pan-cathepsin inhibitor K777 (10 µM, blue lines/symbols). Data are mean signal measured by relative fluorescence units (RFU) ± SEM. n=4. All statistics were p&gt;0.05 calculated by one-way ANOVA on area under curve (AUC) of data with Dunnett’s multiple comparison’s test. (<bold>G–I</bold>) qPCR data showing gene expression (relative to wild-type untreated) of male wild-type (black) and <italic>Cst7</italic><sup>-/-</sup> (red) microglia stimulated with LPS (100 ng/mL, 24 hr), IL-4 (20 ng/mL, 24 hr) or apoptotic SH-SH5Y cells (2:1 ratio, 24 hr). Genes tested were <italic>Arg1</italic> (<bold>G</bold>), <italic>Il1b</italic> (<bold>H</bold>), and <italic>Trem2</italic> (<bold>I</bold>). (K and J) IL-1β secretion from male wild-type (black) and <italic>Cst7</italic><sup>-/-</sup> (red) microglia treated with LPS (1 µg/mL, 4 hr) or LPS+silica (varying dose, 4 hr (<bold>K</bold>) or 300 µg/mL, varying time (<bold>J</bold>)) to activate the NLRP3 inflammasome. Data are mean secretion/expression + SEM. n=4.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Investigating Cst7 knockout on microglial cytokine secretion.</title><p>Multiplex bead-based ELISA data from male wild-type (black) and <italic>Cst7</italic><sup>-/-</sup> (red) microglia stimulated with LPS (100 ng/mL, 24 hr) or IL-4 (20 ng/mL, 24 hr). Data are mean ± SEM. n=4.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Investigating Cst7 knockdown in BV-2 cells vitro.</title><p>(<bold>A</bold>) qPCR data of <italic>Cst7</italic> expression in BV-2 cells treated with scrambled control siRNA (black) or siRNA targeting <italic>Cst7</italic> (red). (<bold>B</bold>) IL-6 secretion from BV-2 cells treated with scrambled control siRNA (black) or siRNA targeting <italic>Cst7</italic> (red) following stimulation with LPS (100 ng/mL, 24 hr) or IL-4 (20 ng/mL, 24 hr). (<bold>C–E</bold>) qPCR data of gene expression in BV-2 cells treated with scrambled control siRNA (black) or siRNA targeting <italic>Cst7</italic> (red) before stimulation with LPS (100 ng/mL, 24 hr) or IL-4 (20 ng/mL, 24 hr). Genes tested were <italic>Arg1</italic> (<bold>C</bold>), <italic>Il1b</italic> (<bold>D</bold>), and <italic>Trem2</italic> (<bold>E</bold>). Data are shown as mean + SEM. n=5. **p&lt;0.01 by one-sample t-test against hypothetical value of 100.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Investigating Cst7 knockout from App<sup>NL-G-F</sup> mice <italic>in vitro</italic>.</title><p>(<bold>A</bold>) Yield of isolated microglia from <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and App<sup>NL-G-F</sup><italic>Cst7</italic><sup>-/-</sup> (red) mice. (<bold>B</bold>) IL-6 secretion from <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) cultured microglia treated with LPS (100 ng/mL, 24 hr). (<bold>C</bold>) IL-1β secretion from <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) cultured microglia treated with LPS (100 ng/mL, 24 hr) or LPS (1 µg/mL, 4 hr)+silica (300 µg/mL, 4 hr) to activate the NLRP3 inflammasome. (<bold>D</bold>) TNFα secretion from <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) cultured microglia treated with LPS (100 ng/mL, 24 hr). Data are presented as mean cytokine concentration in pg/mL + SEM. (<bold>E</bold>) Uptake and degradation of HiLyte647-tagged Aβ<sub>1-42</sub> from female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) cultured microglia. (<bold>F</bold>) Uptake and degradation of HiLyte647-tagged Aβ<sub>1-42</sub> from BV-2 cells treated with vehicle (0.5% DMSO, black), K777 (10 µM, green), or Ca074Me (100 µM, orange). (<bold>G</bold>) Lysosomal proteolysis measured by de-quenching of DQ-BSA from female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) cultured microglia. (<bold>H</bold>) Uptake of HiLyte647-tagged Aβ<sub>1-42</sub> from female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) cultured microglia. Data are shown as mean ± SEM. n=4–5. ***p&lt;0.001 calculated by one-way ANOVA on area under curve (AUC) of data with Dunnett’s multiple comparison’s test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig5-figsupp4-v2.tif"/></fig></fig-group><p>We then used this validated system to compare functional properties of microglia isolated from female <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> mice. First, we showed that <italic>Cst7</italic> knockout had no effect on isolation yield (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4A</xref>) and observed no differences in inflammatory cytokine secretion in response to LPS or NLRP3 activation stimulus silica (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4B–D</xref>), as predicted from our previous RNASeq analysis in female mice. Next, we tested whether <italic>Cst7</italic> plays a role in endolysosomal processes such as phagocytosis or lysosomal degradation. We used a pulse-chase live-imaging assay and found that <italic>Cst7</italic> deletion does not affect degradation of Aβ<sub>1-42</sub> (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4E</xref>), a process dependent on cathepsins as it was inhibited by broad-spectrum inhibitors K777 and Ca074-Me (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4F</xref>). We also showed that <italic>Cst7</italic> deletion does not affect intracellular activity of cathepsins L and C (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>), targets of cystatin-F (<xref ref-type="bibr" rid="bib21">Hamilton et al., 2008</xref>), or microglial lysosomal hydrolysis (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4G</xref>). These data would suggest that the increased microglial Aβ burden <italic>in vivo</italic> observed in <xref ref-type="fig" rid="fig4">Figure 4A</xref> is not due to decreased degradative capacity and may be due increased phagocytosis. To test this, we performed uptake/phagocytosis assays on microglia isolated from 12-month female <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic>. To remove the confounding factor that female <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> will already contain more Aβ (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>) and this may influence further Aβ uptake, we used myelin debris tagged with the pH-sensitive dye pHrodo Red. We found that <italic>Cst7</italic> deletion led to a significant increase in microglial phagocytosis of myelin debris (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). We also tested uptake with fluorescently tagged Aβ<sub>1-42</sub> and found a trend towards increased uptake of Aβ<sub>1-42</sub> (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4H</xref>).</p><p>Together, these data suggest that, in females, <italic>Cst7/</italic>CF negatively regulates phagocytosis but does not affect lysosomal proteolysis or PRR-driven inflammatory cytokine production in microglia from the <italic>App<sup>NL-G-F</sup></italic> model of amyloid-driven AD.</p></sec><sec id="s2-6"><title>Effect of <italic>Cst7</italic> deletion on disease pathology</title><p>Having discovered that <italic>Cst7</italic> plays sex-dependent regulatory roles on microglial phenotype and function in the <italic>App<sup>NL-G-F</sup></italic> model of amyloid-driven AD, we sought to determine if this is associated with effects on disease pathology. Therefore, we studied the Aβ plaques in 12-month male and female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> mice across brain regions. We observed the greatest plaque burden in the cortex and dorsal subiculum followed by the hippocampus (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) and, as expected, the cerebellum was largely devoid of plaque pathology. Next, we compared plaque burden within each area between <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> male and female mice. In males, there was no effect of <italic>Cst7</italic> genotype on plaque burden in any region (<xref ref-type="fig" rid="fig6">Figure 6B–F</xref>). Surprisingly, despite an increased lysosomal burden (<xref ref-type="fig" rid="fig3">Figure 3F</xref>) and intramicroglial Aβ load (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) in female <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> mice, there was no decrease in amyloid plaque burden in any region. In fact, the reverse pattern was evident in some areas, most notably in the subiculum (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). In order to further probe the increase in amyloid pathology in the subiculum, we used MeX04 labelling of the dense cores of Aβ plaques and counted the number of plaques in this region. We observed a significant although modest increase in plaque number specifically in the females (<xref ref-type="fig" rid="fig6">Figure 6G</xref>, quantification in <xref ref-type="fig" rid="fig6">Figure 6H</xref>) without any difference in average plaque size detected (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Together, these data suggest that <italic>Cst7</italic>/CF plays a negative regulatory role on microglial endolysosomal function in female AD mice and show that removal of this block and resultant increase in phagocytosis in <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> females is associated with increased plaque pathology. Finally, we assessed whether <italic>Cst7</italic> deletion had any effect on gross synapse coverage using synaptophysin (Sy38) immunostaining and thioflavin S (ThioS) to localise plaques. We observed loss of Sy38 coverage around plaques (<xref ref-type="fig" rid="fig6">Figure 6I</xref>) and a small but significant decrease in coverage between <italic>App<sup>NL-G-F</sup>/Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup></italic> brains only in females (<xref ref-type="fig" rid="fig6">Figure 6J</xref>). This reflects the effect observed with plaque coverage above suggesting the increased plaque burden in <italic>Cst7<sup>-/</sup></italic><sup>-</sup> female mice may lead to increased synapse loss.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Investigating the effect of <italic>Cst7</italic> deletion on disease pathology.</title><p>(<bold>A</bold>) % Aβ coverage measured by 6E10 3,3'-diaminobenzidine (DAB) staining in cortex (blue), hippocampus (red), subiculum (green), cerebellum (magenta), and whole brain (grey) of male and female <italic>App<sup>NL-G-F</sup></italic> brains. (<bold>B–F</bold>) % Aβ coverage in the cortex (<bold>B</bold>), hippocampus (<bold>C</bold>), subiculum (<bold>D</bold>), cerebellum (<bold>E</bold>), and whole brain (<bold>F</bold>) of male and female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7</italic><sup>-/-</sup> (red) mice. Points are measured by thresholding of whole region area in sagittal section. Bars represent mean + SEM % coverage. n=10–12. *p&lt;0.05, **p&lt;0.01 calculated by two-way ANOVA with Sidak’s multiple comparisons post hoc test. (<bold>G</bold>) Example images from subicula of female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (left) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (right) mice stained with MeX04 (blue). Scale bars are 50 μm. (<bold>H</bold>) Quantification of (<bold>G</bold>). MeX04+ plaque count in the subicula of female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) mice. Points are number of plaques from a single field of view for each mouse. Bars are mean plaque count + SEM. n=10–12. $p&lt;0.05 calculated by two-way Mann-Whitney test. (<bold>I</bold>) Example image of a plaque with Thio S (blue) and synapses stained with synaptophysin (red) in <italic>App<sup>NL-G-F</sup></italic> brain. Plaque border is highlighted in yellow. (<bold>J</bold>) Quantification of (<bold>I</bold>) measuring coverage of synaptophysin. Bars represent mean + SEM % coverage. n=5–12. *p&lt;0.05 calculated by two-way ANOVA with Tukey’s multiple comparisons post hoc test.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data associated with <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title><p>(<bold>A</bold>) % Aβ coverage measured by 6E10 3,3'-diaminobenzidine (DAB) staining in cortex, hippocampus, subiculum, cerebellum, and whole brain of male and female <italic>App<sup>NL-G-F</sup></italic> brains. (<bold>B–F</bold>) % Aβ coverage in the cortex (<bold>B</bold>), hippocampus (<bold>C</bold>), subiculum (<bold>D</bold>), cerebellum (<bold>E</bold>), and whole brain (<bold>F</bold>) of male and female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and <italic>App</italic><sup><italic>NL-G-F</italic></sup><italic>Cst7</italic><sup>-/-</sup> mice. Points are measured by thresholding of whole region area in sagittal section. (<bold>H</bold>) Quantification of MeX04+ plaque count in the subicula of female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup>. (<bold>J</bold>) Quantification of % coverage of synaptophysin in the cortex of male and female wild-type, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> brains.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85279-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Investigating the role of Cst7 in plaque burden.</title><p>Area of MeX04+ plaques in the subiculum of male and female <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> (blue) and <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> (red) brains. Bars are mean plaque area + SEM. n=10–12.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-fig6-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Changes in microglial cells have been heavily implicated in the pathogenesis of AD, particularly supported by genetics studies, where expression of over 50% of risk genes is enriched in microglia (<xref ref-type="bibr" rid="bib22">Hansen et al., 2018</xref>). Notably, a transcriptomic profile has emerged involving <italic>Trem2</italic>-dependent downregulation of homeostatic genes and upregulation of a signature characterised by genes involved in phagocytosis, lipid handling, and endolysosomal transport (<xref ref-type="bibr" rid="bib8">Deczkowska et al., 2018</xref>). One of the most robustly upregulated of these genes, <italic>Cst7</italic> (CF), is believed to be involved in protease inhibition. However, the cellular functions controlled by <italic>Cst7</italic>/CF in microglia and whether Cst7/CF has a disease-modifying role in AD-related CNS proteinopathy has not been explored previously. Here, we reveal that <italic>Cst7</italic>/CF plays a sexually dimorphic role in microglia in an amyloid-driven AD model, acting as a restraint on microglial endolysosomal activity and phagocytosis specifically in female mice, that when absent results in subtle aggravation of Aβ pathology and synapse loss.</p><p>Since their initial description in 2017, the DAM/MGnD/ARM gene signature has been extensively investigated with over 4000 citations between the three papers describing them in 5 years. However, beyond GO analysis, there is surprisingly little understanding of what many of the hallmark genes comprising this signature functionally do in the context of neurodegenerative disease. This is the first study to our knowledge to test the functional role of <italic>Cst7</italic>, one of the most consistently replicated markers of this cell state transcriptomic signature, in β-amyloid-driven pathology. Perhaps counterintuitively, <italic>Cst7</italic> (a reported cysteine protease inhibitor) is robustly upregulated in microglia alongside concomitant upregulation of cysteine proteases such as cathepsins D, B, L, and Z. In fact, such internal regulation systems are not uncommon in inflammation biology, where proinflammatory mediators such as IL-1β and IL-18 are negatively regulated by co-expressed IL-1 receptor antagonist and IL-18 binding protein, respectively (<xref ref-type="bibr" rid="bib29">Hurme and Santtila, 1998</xref>; <xref ref-type="bibr" rid="bib11">Dinarello et al., 2013</xref>). We therefore hypothesise that <italic>Cst7</italic>/CF is upregulated along with numerous cathepsin genes in order to prevent potentially harmful protease activity (<xref ref-type="bibr" rid="bib62">Turk et al., 2012</xref>). In this study, we show that <italic>Cst7</italic>/CF knockout triggers an increase in microglial lysosomal activity and amyloid uptake. Intriguingly, this did not seem to depend on overactive intracellular cathepsin activity, which intuitively would have been expected to increase with the lack of negative regulator. It is possible that CF deficiency does in fact lead to an increase in cathepsin activity, but CF itself is secreted and only impairs secreted cathepsins which are responsible for promoting phagocytosis. Indeed, studies have suggested that CF can be secreted and that there is a role for secreted cathepsins in phagocytosis (<xref ref-type="bibr" rid="bib39">Liuzzo et al., 1999</xref>; <xref ref-type="bibr" rid="bib21">Hamilton et al., 2008</xref>). This is also consistent with the observation that exogenously applied cystatin C can block phagocytosis in human polymorphonuclear neutrophils (<xref ref-type="bibr" rid="bib36">Leung-Tack et al., 1990</xref>).</p><p>Another key implication from this study is that of sexual dimorphism in disease. Here, we show stark differences in the effect of <italic>Cst7</italic> deletion between males and females at both the gene and protein level. Although there is a relative paucity of studies investigating male <italic>vs.</italic> female microglia in homeostasis and disease, numerous differences have been identified (<xref ref-type="bibr" rid="bib41">Lynch, 2022</xref>). In general, male microglia are believed to have higher baseline activity in processes such as inflammation, antigen presentation, and phagocytosis; whereas female microglia are more associated with neuroprotection and the DAM/ARM/MGnD signature in ageing and disease (<xref ref-type="bibr" rid="bib20">Guneykaya et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Kodama and Gan, 2019</xref>; <xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Villa et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Guillot-Sestier et al., 2021</xref>). These differences in baseline properties are only partially dependent on hormonal signalling as masculinisation of females by ovariectomy and hormone replacement only partially recapitulated male microglia (<xref ref-type="bibr" rid="bib66">Villa et al., 2018</xref>). Indeed, sexual dimorphism of microglia in adults appears a cell-intrinsic phenomenon as female microglia transplanted in male brains retain their transcriptional profile and reduce infarct size in males after ischemic stroke (<xref ref-type="bibr" rid="bib66">Villa et al., 2018</xref>). Interestingly, we generally do not observe marked sexual dimorphism in microglia in wild-type or <italic>App<sup>NL-G-F</sup></italic> mice. However, DAM/ARM/MGnD gene expression was higher in female <italic>vs.</italic> male microglia and lysosomal activity was markedly higher in male <italic>vs.</italic> female brains measured by LAMP2 staining, which is consistent with the literature (<xref ref-type="bibr" rid="bib20">Guneykaya et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>). Importantly, we observed a substantial interaction effect of <italic>Cst7</italic> deletion and sex, whereby removal of the <italic>Cst7</italic> gene led to an ‘unlocking’ of sexual dimorphism in our cohort. This is most clearly demonstrated by DEGs between male <italic>vs.</italic> female microglia rising from 33 in <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> mice to 240 in <italic>App<sup>NL-G-F</sup>Cst7</italic><sup>-/-</sup> mice. This sex-dependent interaction effect has previously been observed in studies investigating the cystatin/cathepsin system, where deletion of <italic>Cst3</italic> (cystatin C) led to protection in the EAE model of multiple sclerosis in females but not males (<xref ref-type="bibr" rid="bib24">Hoghooghi et al., 2020</xref>). This effect appeared to be sensitive to hormones as ovariectomy or castration followed by testosterone or estrogen/progesterone administration effectively reversed the effect of <italic>Cst3</italic> knockout. The precise molecular mechanism underpinning this was not explored but could include differential post-translational modification. The inhibitor effect of cystatin C on phagocytosis is dependent on N-terminal truncation (<xref ref-type="bibr" rid="bib36">Leung-Tack et al., 1990</xref>) whilst more recently an N-terminal processing event has been identified for CF (<xref ref-type="bibr" rid="bib21">Hamilton et al., 2008</xref>). Understanding whether N-terminal processing events are sex-specific would be a useful step in determining how genetic deletion can have differential effects dependent on sex. Indeed, sex:genetics interactions are not uncommon in neurodegenerative disease, with various risk variants posing greater or lesser effect on risk in men or women (<xref ref-type="bibr" rid="bib14">Gamache et al., 2020</xref>). One example of this interaction is <italic>APOE</italic>, in which the presence of the E4 allele confers a greater AD risk in women than in men (<xref ref-type="bibr" rid="bib2">Altmann et al., 2014</xref>).</p><sec id="s3-1"><title>Ideas and speculation</title><p>Here, we observed that <italic>Cst7</italic>/CF played a role in microglial amyloid uptake and endolysosomal gene expression only in females. Surprisingly, this did not lead to a decrease in Aβ plaque pathology as might be expected but an increase, although of modest degree, in specific brain areas. This discovery raises the important question of the relationship between microglial phagocytosis and plaques. It is generally considered that an increase in microglial phagocytosis should lead to reduction in plaque burden and benefit in disease (<xref ref-type="bibr" rid="bib23">Heneka et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Tejera et al., 2019</xref>). However, recent studies have emerged to suggest that phagocytosing microglia may in fact act to ‘build’ plaques rather than dismantle them. For example, microglia lacking TAM receptors Axl and Mer fail to take up Aβ which leads to an overall decrease in dense-core plaque formation (<xref ref-type="bibr" rid="bib27">Huang et al., 2021</xref>), microglia can ‘seed’ plaques from disease tissue into engrafted, non-affected regions (<xref ref-type="bibr" rid="bib9">d’Errico et al., 2022</xref>), and either genetic or pharmacological depletion of microglia leads to a reduction in plaque burden/intensity accompanied by increase in cerebral amyloid angiopathy (<xref ref-type="bibr" rid="bib57">Spangenberg et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Kiani Shabestari et al., 2022</xref>) perhaps through redistributing Aβ. Interestingly, only female mice were used in two of these studies (<xref ref-type="bibr" rid="bib27">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">d’Errico et al., 2022</xref>), which parallels our sex-specific findings with <italic>Cst7</italic>. In the above studies, microglial depletion/inactivation leading to reduced parenchymal plaque burden is generally detrimental in disease. In contrast, we find indications in our study that the increased microglial phagocytosis and concomitant increase in plaque burden in <italic>Cst7<sup>-/-</sup></italic> females may be detrimental. This is most likely due to direct effect of increased plaque burden leading to increased synapse loss. However, we cannot confirm whether this apparent synapse loss is a result of increased microglial uptake (<xref ref-type="bibr" rid="bib25">Hong et al., 2016</xref>) or direct synaptotoxicity (<xref ref-type="bibr" rid="bib64">Tzioras et al., 2023b</xref>). We speculate that <italic>Cst7</italic>/CF may contribute to restraining plaque formation and protecting against synapse loss by influencing microglial endolysosomal function in a dose-dependent manner.</p><p>We were also surprised that there was no change in plaque burden in males, where microglia had a reduction in inflammatory profile. Studies have suggested that reducing inflammatory cytokine secretion may reduce plaque formation and increase Aβ uptake (<xref ref-type="bibr" rid="bib23">Heneka et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Tejera et al., 2019</xref>). These effects may be linked specifically to the NLRP3-caspase-1-ASC-IL-1β axis and that a more general reduction in inflammatory genes is not capable of phenocopying <italic>Nlrp3<sup>-/</sup></italic><sup>-</sup> mice. Additionally, we observe a relatively mild reduction in inflammatory genes in male <italic>App<sup>NL-G-F</sup>Cst7<sup>-/</sup></italic><sup>-</sup> mice with fold changes mostly below 2 <italic>vs. App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic> controls. We speculate that either complete genetic deletion or strong inhibition with chemical compounds is required to yield pro-phagocytic effects. We also note in our study that male <italic>Cst7<sup>-/-</sup></italic> microglia had reduced expression of lysosomal proteins, possibly counteracting the reduction in inflammatory gene expression.</p></sec><sec id="s3-2"><title>Limitations</title><p>Although these data provide novel insight into the sex-dependent role of microglial gene <italic>Cst7</italic> in AD, it is important to acknowledge some caveats of the study that point to potential future investigations into this complex biological phenomenon. Here, we investigated CF function solely in mouse. While human data on microglial CF is limited, studies have shown that (where detected) CF is expressed predominantly in myeloid cells (<xref ref-type="bibr" rid="bib72">Zhang et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Mathys et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Schirmer et al., 2019</xref>; <xref ref-type="bibr" rid="bib58">Srinivasan et al., 2020</xref>) and identified CF expression in microglia around plaques in AD (<xref ref-type="bibr" rid="bib46">Ofengeim et al., 2017</xref>) and <italic>CST7</italic> enrichment in AD-associated microglia clusters by single nucleus RNA sequencing (snRNASeq) (<xref ref-type="bibr" rid="bib15">Gerrits et al., 2021</xref>). CST7 protein has also been detected as higher levels predicted slower tau accumulation and cognitive decline with a significant sex interaction effect (<xref ref-type="bibr" rid="bib49">Pereira et al., 2022</xref>). However, CF/<italic>CST7</italic> has also remained undetected in similar immunostaining and snRNASeq studies (<xref ref-type="bibr" rid="bib45">Nuvolone et al., 2017</xref>; <xref ref-type="bibr" rid="bib73">Zhou et al., 2020</xref>). While the reason for this discrepancy is unclear, it may be partially due to sex. Indeed, there was a greater ratio samples from female brains in <xref ref-type="bibr" rid="bib15">Gerrits et al., 2021</xref> than in <xref ref-type="bibr" rid="bib73">Zhou et al., 2020</xref>, as would be expected if <italic>CST7</italic> plays a more important role in female microglia. These data further demonstrate the importance of stratifying studies by sex. Additionally, while mechanistic studies investigating CF/<italic>CST7</italic> in human microglia differentiated from inducible pluripotent stem cells would be valuable, our discovery that CF function is revealed in mouse microglia only when cells are taken from disease context would suggest more complex models are required. Indeed, a recent study utilised overexpression of TREM2 in human microglial cells to show that driving <italic>CST7</italic> expression led to inhibition of phagocytosis in a <italic>CST7</italic>-dependent manner (<xref ref-type="bibr" rid="bib52">Popescu et al., 2023</xref>). These data suggest the functional role of CF is not species-specific and provide important translational evidence. Finally, while this study details the discovery of the mechanistic role of CF/<italic>Cst7</italic> in an amyloid-driven AD model, the precise mechanism(s) by which <italic>Cst7</italic> deletion affects microglia only in females and the biological reason for the accelerated DAM/MGnD/ARM programme in females now demonstrated in multiple studies remains unknown. This phenomenon may go some way to explaining the sexual dimorphism we observe in this study, that is, the effect of <italic>Cst7</italic> deletion at 12 months in females may be mirrored in males at later disease stages. However, although we do observe increased expression of sex-regulated DAM genes such as <italic>Gpnmb</italic> and <italic>Spp1</italic>, we do not find differential expression of <italic>Cst7</italic> itself in females <italic>vs.</italic> males or most other genes in <italic>App<sup>NL-G-F</sup></italic>. Additionally, we find a qualitatively different pattern of altered gene expression from <italic>Cst7</italic> deletion in female <italic>vs.</italic> male <italic>App<sup>NL-G-F</sup></italic> mice rather than similar effects of differing magnitude. This suggests that that a sex-intrinsic mechanism rather than a simple ‘lagging’ in males is a more likely explanation underpinning <italic>Cst7</italic> deletion sex-dependent effects. Future work should investigate this further with ovariectomy/hormone replacement and transplantation studies, such as those performed by <xref ref-type="bibr" rid="bib66">Villa et al., 2018</xref>.</p><p>In summary, our data provide key mechanistic insight into the role of one of the most robustly upregulated genes in disease-reactive microglia. These data suggest that <italic>Cst7</italic>/CF regulates some key aspects of microglial function, in a sex-dependent manner, and that these are associated with pathology-influencing effects in an amyloid-driven AD model that also manifest differently in males and females. We hypothesise that <italic>Cst7</italic>/CF plays a part in an internal regulatory system that balances the two crucial processes of phagocytosis and inflammatory signalling, which are sexually dimorphic processes. More broadly, and in view of the poorly understood functions of many other recently described hallmark microglial disease-related state mediators, it is imperative to consider interactions with sex when investigating their cellular and disease roles.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>App<sup>NL-G-F</sup></italic></td><td align="left" valign="bottom">DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nn.3697">10.1038/nn.3697</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Cst7<sup>-/-</sup></italic></td><td align="left" valign="bottom">DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.immuni.2016.03.003">10.1016/j.immuni.2016.03.003</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">BV2</td><td align="left" valign="bottom">Collaborator</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0182">RRID: CVCL_0182</ext-link></td><td align="left" valign="bottom">Authenticated (STR profiling)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">SH-SY5Y</td><td align="left" valign="bottom">Collaborator</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0019">RRID: CVCL_0019</ext-link></td><td align="left" valign="bottom">Authenticated (STR profiling)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Synaptoneurosome from AD brain</td><td align="left" valign="bottom">DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xcrm.2023.101175">10.1016/j.xcrm.2023.101175</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">AMREC (approval number 15-HV-016)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Purified myelin</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods ‘Myelin purification and pHrodo tagging’</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Ly6C- Alexa Fluor 488<break/>(Rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 128021</td><td align="left" valign="bottom">FACS 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-P2Y12 – PE<break/>(Rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 848003</td><td align="left" valign="bottom">FACS 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MHCII – PEDazzle594<break/>(Rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 107647</td><td align="left" valign="bottom">FACS 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD45 – PE-Cy7<break/>(Rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103113</td><td align="left" valign="bottom">FACS 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti- CD11c – APC<break/>(Armenian Hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 117309</td><td align="left" valign="bottom">FACS 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti- CD11b – BV711<break/>(Rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 848003</td><td align="left" valign="bottom">FACS 1:50</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IBA1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Wako</td><td align="left" valign="bottom">Cat# 019-19741</td><td align="left" valign="bottom">IF 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti- Aβ (6E10) (Mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 803001</td><td align="left" valign="bottom">IF/DAB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LAMP2 (Rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108501</td><td align="left" valign="bottom">IF 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Synaptophysin (Sy38) (Mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab8049</td><td align="left" valign="bottom">IF 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit IgG Alexa Fluor 488<break/>(Goat polyclonal)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A-11008</td><td align="left" valign="bottom">IF 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IgG Alexa Fluor 555<break/>(Donkey polyclonal)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A-31570</td><td align="left" valign="bottom">IF 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat IgG Alexa Fluor 647<break/>(Goat polyclonal)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A-21247</td><td align="left" valign="bottom">IF 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Biotinylated</td><td align="left" valign="bottom">Vector Labs</td><td align="left" valign="bottom">Cat# ba-9200</td><td align="left" valign="bottom">DAB 1:100</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Methoxy X04</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">Cat# 4920</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cathepsin L probe</td><td align="left" valign="bottom">Bachem</td><td align="left" valign="bottom">Cat# 4003379</td><td align="left" valign="bottom">Z-Phe-Arg-AMC</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cathepsin C probe</td><td align="left" valign="bottom">Bachem</td><td align="left" valign="bottom">Cat# 4003759</td><td align="left" valign="bottom">H-Gly-Phe-AMC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Cst7_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ACCAATAACCCAGGAGTGCTTA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Cst7_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGACCCAGACTTCAGAGTAGCA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Arg1_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGAGACCACAGTCTGGCAGTTGGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Arg1_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGACACAGGTTGCCCATGCAGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Il1b_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CGACAAAATACCTGTGGCCTTGGGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Il1b_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGCTTGGGATCCACACTCTCCAGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trem2_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CTGCTGATCACAGCCCTGTCCCAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trem2_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CCCCCAGTGCTTCAAGGCGTCATA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Gapdh_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGCATCCACTGGTGCTGCCAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Gapdh_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ACTTGGCAGGTTTCTCCAGGCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Lilrb4a_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ATGGGCACAAAAAGAAGGCTAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Lilrb4a_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCATAGGTTACATCCTGGGTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ndufv1_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ATTTTCTCGGCGGGTTGGTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ndufv1_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CACCTTTCAGCCTCCAGTCA</named-content></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DuoSet ELISA – IL-1β</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY401</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DuoSet ELISA – IL-6</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY406</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DuoSet ELISA – TNFα</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY411</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNAscope 2.5 HD Duplex Assay</td><td align="left" valign="bottom">Biotechne</td><td align="left" valign="bottom">Cat# 322436</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNAscope probes – Cst7</td><td align="left" valign="bottom">Biotechne</td><td align="left" valign="bottom">Cat# 498711-C2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNAscope probes – Lilrb4a</td><td align="left" valign="bottom">Biotechne</td><td align="left" valign="bottom">Cat# 1260291-C2</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p><italic>App<sup>NL-G-F</sup></italic> mice (<xref ref-type="bibr" rid="bib54">Saito et al., 2014</xref>) were provided by the RIKEN BRC through the National BioResource Project of the MEXT/AMED, Japan. <italic>Cst7<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="bib43">Matthews et al., 2016</xref>) were obtained from Colin Watts, University of Dundee, UK. C57Bl/6J mice used for myelin preparations were purchased from Charles River, UK. Animals were maintained under standard laboratory conditions: ambient temperatures of 21°C (±2°C), humidity of 40–50%, 12 hr light/dark cycle, <italic>ad libitum</italic> access to water, and standard rodent chow. Genotype groups were randomised during the study and experimenters were blinded to genotype during all experiments. All animal experiments were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 and approved by the Home Office and the local Animal Ethical Review Group, University of Edinburgh. Experimental design, analysis, and reporting followed the ARRIVE 2.0 guidelines (<xref ref-type="bibr" rid="bib48">Percie du Sert et al., 2020</xref>). Genotyping was performed using optimised assays from Transnetyx. Methoxy X-04 (MeX04, BioTechne) was reconstituted in DMSO at 10 mg/mL before diluting to 0.33 mg/mL in 6.67% Cremaphor EL (Fluka), 90% PBS (Merck). MeX04 was administered by intraperitoneal injection at 10 mg/kg 2.5 hr before animals were terminated.</p></sec><sec id="s4-2"><title>Microglial FACS isolation</title><p>Microglia were isolated by enzymatic digestion and FACS as follows. Brains from 12-month-old male and female <italic>App<sup>Wt/Wt</sup>Cst7<sup>+/+</sup></italic>, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> mice were isolated by terminally anaesthetising with 3% isoflurane (33.3% O<sub>2</sub> and 66.6% N<sub>2</sub>O) and transcardial perfusion with ice-cold DEPC-treated 0.9% NaCl, 0.4% trisodium citrate. Brains were immediately separated down the midline then the right hemisphere placed into ice-cold HBSS (ThermoFisher) and minced using a 22A scalpel. Minced hemi-brains were then centrifuged (300 × <italic>g</italic>, 2 min) and digested using the MACS Neural Dissociation Kit (Miltenyi) according to the manufacturer’s instructions. Briefly, brain tissue was incubated in enzyme P (50 μL/hemi-brain) diluted in buffer X (1900 μL/hemi-brain) for 15 min at 37°C under gentle rotation before addition of enzyme A (10 μL/hemi-brain) in buffer Y (20 μL/hemi-brain) and further incubation for 20 min at 37°C under gentle rotation. Following digestion, tissue was dissociated mechanically using a Dounce homogeniser (loose pestle, 20 passes) on ice and centrifuged (400 × <italic>g</italic>, 5 min at 4°C). To remove myelin, tissue was resuspended in 35% isotonic Percoll (GE Healthcare) in HBSS overlaid with 1× HBSS and centrifuged (800 × <italic>g</italic>, 30 min, 4°C, no brake). Following centrifugation, the supernatant and myelin layers were discarded and the pellet resuspended in 100 μL FACS buffer (PBS, 0.1% low endotoxin bovine serum albumin [BSA, Merck], 25 mM HEPES) and transferred to V-bottomed 96-well plates (ThermoFisher). Cell suspensions were treated with anti-mouse-CD16/32 to block Fc receptors (BioLegend, 5 μg/mL, 20 min at 4°C) before washing and transferring to PBS and treating with Zombie NIR (BioLegend, 1:100, 15 min at room temperature [RT]) to label dead cells. Next, cells were stained with antibodies (<xref ref-type="table" rid="table1">Table 1</xref> ) to identify microglia and incubated for 20 min at 4°C. Antibodies (BioLegend) used were as follows.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Antibodies used for flow cytometry.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Fluorochrome</th><th align="left" valign="bottom">Antigen</th><th align="left" valign="bottom">Clone</th><th align="left" valign="bottom">Lot</th><th align="left" valign="bottom">Cat number</th><th align="left" valign="bottom">Stock concentration (mg/mL)</th><th align="left" valign="bottom">Dilution</th></tr></thead><tbody><tr><td align="left" valign="bottom">Alexa Fluor 488</td><td align="left" valign="bottom">Ly6C</td><td align="left" valign="bottom">HK1.4</td><td align="left" valign="bottom">B248739</td><td align="char" char="." valign="bottom">128021</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">500</td></tr><tr><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">P2Y12</td><td align="left" valign="bottom">S16007D</td><td align="left" valign="bottom">B298459</td><td align="char" char="." valign="bottom">848003</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">200</td></tr><tr><td align="left" valign="bottom">PEDazzle594</td><td align="left" valign="bottom">MHCII</td><td align="left" valign="bottom">M5/114.15.2</td><td align="left" valign="bottom">B216062</td><td align="char" char="." valign="bottom">107647</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">200</td></tr><tr><td align="left" valign="bottom">PE-Cy7</td><td align="left" valign="bottom">CD45</td><td align="char" char="hyphen" valign="bottom">30-F11</td><td align="left" valign="bottom">B271123</td><td align="char" char="." valign="bottom">103113</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">200</td></tr><tr><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">CD11c</td><td align="left" valign="bottom">N418</td><td align="left" valign="bottom">B280313</td><td align="char" char="." valign="bottom">117309</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">200</td></tr><tr><td align="left" valign="bottom">BV711</td><td align="left" valign="bottom">CD11b</td><td align="left" valign="bottom">M1/70</td><td align="left" valign="bottom">B305911</td><td align="char" char="." valign="bottom">101241</td><td align="char" char="." valign="bottom">0.005</td><td align="char" char="." valign="bottom">50</td></tr></tbody></table></table-wrap><p>Following incubation, cells were washed with FACS buffer, resuspended in 500 μL FACS buffer and transferred to 5 mL round-bottom FACS tubes through cell strainer caps (BD). Cells were sorted through a 100 μm nozzle on a FACS Aria II (BD) at the QMRI Flow Cytometry Cell Sorting Facility, University of Edinburgh with the following strategy (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Debris were eliminated using forward scatter (area) vs. side scatter (area), singlets were isolated using forward scatter (area) vs. forward scatter (height), dead cells were eliminated with Zombie NIR, monocytes were eliminated by gating out Ly6C+ cells, and microglia were defined as CD11b+/CD45+. All antibodies were validated using appropriate fluorescence minus one controls. Microglia were sorted directly into 500 μL RLT buffer (QIAGEN) and 20,000 CD11b+/CD45+ events were collected for downstream analysis using FlowJo software.</p></sec><sec id="s4-3"><title>RNA purification, QC, and sequencing</title><p>RNA was purified using RNEasy Plus Micro kits (QIAGEN) according to the manufacturer’s instructions. RNA was quantified and QC’d using a 4200 TapeStation System (Agilent) with a High Sensitivity RNA ScreenTape Assay according to the manufacturer’s instructions. For <italic>in vivo</italic> experiments, RNA was pooled from three to four animals within the same experimental group. RNA within pools was equally distributed in amount between the animals. One ng of total RNA was taken forward for low-input RNA sequencing (Cambridge Genomics). Briefly, cDNA was generated using TakaraBio SMART-Seq v4 Ultra Low Input RNA kit before input into the Illumina Nextera XT library prep. Pooled libraries were sequenced on the NextSeq 500 (Illumina) using the 75 cycle High Output sequencing run kit, spiked with 5% PhiX at a depth of 30 million reads per sample.</p></sec><sec id="s4-4"><title>RNASeq analysis</title><p>Reads were mapped to the mouse primary genome assembly GRCm39, Ensembl release 104 (<xref ref-type="bibr" rid="bib7">Cunningham et al., 2022</xref>) using STAR version 2.7.9a (<xref ref-type="bibr" rid="bib12">Dobin et al., 2013</xref>), and tables of per-gene read counts were summarised using featureCounts version 2.0.2 (<xref ref-type="bibr" rid="bib38">Liao et al., 2014</xref>). Differential expression analysis was performed using DESeq2 (R package version 1.30.1) (<xref ref-type="bibr" rid="bib40">Love et al., 2014</xref>), using an adjusted p-value cut-off of 0.05 to identify genes differentially expressed between conditions. Comparisons carried out were male (M) <italic>App<sup>Wt/Wt</sup>Cst7<sup>+/+</sup> vs.</italic> M <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> female (F) <italic>App<sup>Wt/Wt</sup>Cst7<sup>+/+</sup> vs.</italic> F <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> M <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup> vs.</italic> M <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic>, F <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup> vs.</italic> F <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic>, M <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup> vs.</italic> F <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup></italic>, M <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup> vs.</italic> F <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic>. For each comparison GO enrichment analysis was performed to provide insight into the biological pathways and processes affected; GO enrichment analysis was performed using topGO (<xref ref-type="bibr" rid="bib1">Alexa et al., 2006</xref>) (R package version 2.42.0). Significantly upregulated and downregulated gene sets were compared against annotated GO terms from the categories of ‘biological process’. Selected statistically significant GO:BP terms were then visualised using GraphPad prism v9.</p></sec><sec id="s4-5"><title>qPCR</title><p>Cells were seeded at 75,000 cells/well in a 24-well plate 7 days before stimulation (primary microglia) or 250,000 cells/well in a 24-well plate 18 hr before stimulation (BV-2 cells). On the day of the assay, microglia were treated with vehicle (PBS, 24 hr, Merck), LPS (100 ng/mL, 24 hr, Merck), IL-4 (20 ng/mL, 24 hr, R&amp;D Systems) or apoptotic SH-SY5Y neuroblastoma cells (2:1 ratio neurons:microglia, 24 hr) then lysed in RLT buffer and RNA isolated according to the manufacturer’s instructions. RNA (100–500 ng) was converted to cDNA using SuperScript IV Reverse Transcriptase (ThermoFisher) according to the manufacturer’s instructions. qPCR was performed using PowerUp SYBR Green PCR Master Mix (ThermoFisher) in 384-well format using an qTOWER<sup>3</sup>84 Real-time PCR machine (Analytik Jena). For BV-2 cells, 10 ng cDNA (assuming 100% RNA to cDNA conversion) was loaded per well with 5 pmol primer/well in triplicate in a total volume of 10 μL. For primary microglia experiments, 0.5 ng cDNA was loaded per well. Data were normalised to the expression of the housekeeping gene <italic>Gapdh</italic> or mean <italic>Gapdh</italic> and <italic>Ndufv1</italic> and were analysed using the ΔΔCt method. Primers used are detailed in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Primers used for qPCR.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">Forward</th><th align="left" valign="bottom">Reverse</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Cst7</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ACCAATAACCCAGGAGTGCTTA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TGACCCAGACTTCAGAGTAGCA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Arg1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGAGACCACAGTCTGGCAGTTGGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGACACAGGTTGCCCATGCAGA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Il1b</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CGACAAAATACCTGTGGCCTTGGGC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TGCTTGGGATCCACACTCTCCAGC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Trem2</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTGCTGATCACAGCCCTGTCCCAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCCCCAGTGCTTCAAGGCGTCATA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Gapdh</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TGCATCCACTGGTGCTGCCAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">ACTTGGCAGGTTTCTCCAGGCG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Lilrb4a</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATGGGCACAAAAAGAAGGCTAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGCATAGGTTACATCCTGGGTC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ndufv1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATTTTCTCGGCGGGTTGGTT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CACCTTTCAGCCTCCAGTCA</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-6"><title>Microglial bead-based isolation for <italic>in vitro</italic> studies</title><p>Primary adult mouse microglia were isolated and cultured as described previously (<xref ref-type="bibr" rid="bib17">Grabert and McColl, 2018</xref>). Brains were isolated by terminally anaesthetising with 3% isoflurane (33.3% O<sub>2</sub> and 66.6% N<sub>2</sub>O) and transcardial perfusion with ice-cold 0.9% NaCl. Brains were immediately placed into ice-cold HBSS (ThermoFisher) and minced using a 22A scalpel before centrifugation (300 × <italic>g</italic>, 2 min) and digestion using the MACS Neural Dissociation Kit (Miltenyi) according to the manufacturer’s instructions. Briefly, brain tissue was incubated in enzyme P (50 μL/brain) diluted in buffer X (1900 μL/brain) for 15 min at 37°C under gentle rotation before addition of enzyme A (10 μL/brain) in buffer Y (20 μL/brain) and further incubation for 20 min at 37°C under gentle rotation. Following digestion, tissue was dissociated mechanically using a Dounce homogeniser (loose pestle, 20 passes) on ice and centrifuged (400 × <italic>g</italic>, 5 min at 4°C). To remove myelin, tissue was resuspended in 35% isotonic Percoll (GE Healthcare) overlaid with HBSS and centrifuged (800 × <italic>g</italic>, 40 min, 4°C). Following centrifugation, the supernatant and myelin layers were discarded and the pellet resuspended in MACS buffer (PBS, 0.5% low endotoxin BSA [Merck], 2 mM EDTA, 90 μL/brain). Anti-CD11b microbeads (Miltneyi) were added (10 μL/brain) and the suspension incubated for 15 min at 4°C before running through pre-rinsed (MACS buffer) LS columns attached to a magnet (Miltenyi). After washing with 12 mL MACS buffer, columns were removed from the magnet and cells retained (microglia) were flushed in 5 mL MACS buffer. For experiments investigating expression of RNASeq hit genes in non-diseased microglia, cells were immediately lysed in RLT buffer and RNA purified as above. For culture experiments, microglia were resuspended in Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 (DMEM/F-12, ThermoFisher) supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin (PenStrep, Merck), 10% heat-inactivated fetal bovine serum (FBS, ThermoFisher), 50 ng/mL rhTGFβ-1 (Miltenyi), 10 ng/μL mCSF1 (R&amp;D Systems). Microglia were counted using a haemocytometer and plated out onto 24- or 96-well plates (Corning) coated with poly-L-lysine (Merck). Cells were cultured for 7 days with a half media change on day 3. For stimulation experiments, cells were stimulated with LPS, IL-4, or silica particles (US Silica) at concentrations and timepoints as described in each experiment in detail before supernatant was taken and assessed for IL-6, IL-1β, or TNF-α by DuoSet ELISA (R&amp;D Systems) as per the manufacturer’s instructions.</p></sec><sec id="s4-7"><title>Immortalised cell culture</title><p>Murine BV-2 microglial cells (<xref ref-type="bibr" rid="bib4">Blasi et al., 1990</xref>) were cultured in DMEM (ThermoFisher), 10% FBS (ThermoFisher), and 1% PenStrep (Merck). Human SH-SY5Y neuroblastoma cells (ECACC 94030304) were cultured in DMEM/F-12 (ThermoFisher), 10% FBS (ThermoFisher), and 1% PenStrep (Merck). To induce apoptosis, SH-SY5Y cells were plated in a 10 cm dish at 4×10<sup>6</sup> cells/dish and stimulated with UV light (4×15 W UV bulb, 30 hr) before incubation at 37°C for 18 hr. After incubation, cells were removed from dishes using Accutase (Merck) and adjusted to 4×10<sup>6</sup> cells/mL for stimulation onto microglia. All cells were cultured at 37°C, 5% CO<sub>2</sub> in a tissue culture incubator (Panasonic) and handled in a Safe 2020 Class II tissue culture cabinet (ThermoFisher). Cell lines (BV-2 immortalized mouse microglia and SH-SY5Y human neuroblastoma) were obtained from collaborators. Identities of the cell lines were authenticated by STR profiling (American Type Culture Collection) and tested negative for mycoplasma (Mycoplasma Detection Kit, Lonza).</p></sec><sec id="s4-8"><title>BV-2 siRNA knockdown</title><p>Small interfering RNAs (siRNAs) (Silencer-Select, Ambion) targeting <italic>Cst7</italic> were used to induce gene knockdown in BV-2 cells. Cells were plated out at 250,000 cells/well in a 24-well plate 18 hr before knockdown. For transfection of each siRNA (<italic>Cst7</italic> and non-targeting control), a 1:1 ratio of Lipofectamine RNAiMAX (ThermoFisher) and the siRNA, both diluted in Opti-MEM (ThermoFisher), were added to desired cell supernatants, with 10 pmol siRNA and 1.5 μL Lipofectamine RNAiMAX used per well. After 24 hr, cells were stimulated with vehicle (PBS), LPS (100 ng/mL, 24 hr, Merck), or IL-4 (20 ng/mL, 24 hr, R&amp;D Systems). Following stimulation, cells were lysed for RNA analysis and supernatants were analysed for IL-6 content by ELISA (DuoSet, R&amp;D Systems) according to the manufacturer’s instructions.</p></sec><sec id="s4-9"><title>Myelin purification and pHrodo tagging</title><p>Purified myelin was prepared from C57Bl/6J mouse brains. Brains were isolated, digested, and myelin layer fractionated using 35% percoll gradient as described above. Myelin was washed by dilution in HBSS and centrifuged at 400 × <italic>g</italic> for 5 min at 4°C before suspending in 3 mL ice-cold 0.32 M sucrose solution containing protease inhibitor cocktail (Roche). Next, myelin was layered onto 3 mL ice-cold 0.85 M sucrose solution in a 10 mL ultracentrifuge tube (Beckman) before centrifugation at 75,000 × <italic>g</italic> for 30 min at 4°C on a Beckman Ultracentrifuge with MLA-55 rotor (acceleration 7, deceleration 7). Myelin was collected from the 0.32 M:0.85 M interface and placed in 5 mL ice-cold ddH<sub>2</sub>O in a new Beckman ultracentrifuge tube and vortexed before further centrifugation at 75,000 × <italic>g</italic> for 15 min at 4°C (acceleration 9, deceleration 9). Myelin was then reconstituted in 5 mL ddH<sub>2</sub>O and incubated on ice for 10 min before further centrifugation at 12,000 × <italic>g</italic> for 15 min at 4°C (acceleration 9, deceleration 9). This wash and ddH<sub>2</sub>O incubation step was repeated before myelin was again fractionated in 0.32 M:0.85 M sucrose gradient and washed as before. Finally, purified myelin was resuspended in 1 mL sterile PBS and stored at –80°C until further use. Myelin was tagged with pHrodo Red according to the manufacturer’s instructions. Briefly, myelin was centrifuged (10,000 × <italic>g</italic> 10 min) and resuspended in 100 μL pHrodo Red succinimidyl ester (100 μg/mL in PBS 1% DMSO). Myelin was incubated for 45 min at RT in the dark before washing × 2 with 1 mL PBS. Finally, tagged myelin was resuspended in 100 μL, aliquoted, and stored at –20°C for further use.</p></sec><sec id="s4-10"><title>Microglial phagocytosis/degradation assays</title><p>Primary adult mouse microglia were isolated as described above and plated out in 96-well plates at 50,000 cells/well. Cells were cultured for 7 days or 3 days (in the case of cells from <italic>App<sup>NL-G-F</sup></italic> brains) before stimulation. For phagocytosis assays, microglia were first imaged using an IncuCyte S3 Live-Cell Analysis System (Sartorius) in ‘phase’ and ‘red’ channels to gain baseline information on confluence and background fluorescence. Next, cells were stimulated with Aβ<sub>1-42</sub>HiLyte647 (ThermoFisher, 0.5 μM), pHrodo Red <italic>S. aureus</italic> Bioparticles (ThermoFisher, 100 μg/mL), purified mouse myelin tagged with pHrodo Red succinimidyl ester (1:100, ThermoFisher), or isolated human synaptoneurosomes from AD brains (<xref ref-type="bibr" rid="bib59">Tai et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Tzioras et al., 2023a</xref>) tagged with pHrodo Red succinimidyl ester (1:20, ThermoFisher) by media change. Immediately after stimulation, cells were returned to the IncuCyte S3 for imaging in the ‘phase’ and ‘red’ channel with 9 images/well every 15 min for 2–3 hr. Images were analysed using the IncuCyte 2019B Rev2 software (Sartorius) as total integrated intensity in ‘red’ channel normalised to confluence in ‘phase’ channel.</p></sec><sec id="s4-11"><title>Human tissue</title><p>Use of human tissue for synaptoneurosome experiments above was reviewed and approved by the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee, AMREC (approval number 15-HV-016; ACCORD is the Academic and Clinical Central Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian). The Edinburgh Brain Bank is a Medical Research Council funded facility with research ethics committee (REC) approval (11/ES/0022).</p></sec><sec id="s4-12"><title>Cathepsin probe assays</title><p>Cathepsin probe assays were carried out as described in <xref ref-type="bibr" rid="bib21">Hamilton et al., 2008</xref>. Briefly, microglia were isolated and cultured for 3 days as above before cells were lysed in RIPA buffer (60 μL/well, Merck). Next, 25 μL lysate was combined with 175 μL cathepsin probe L (Z-Phe-Arg-AMC, 45 μM, Bachem) or C (H-Gly-Phe-AMC, 56 μM, Bachem) in an assay buffer comprising 150 mM NaCl, 2 mM EDTA, 5 mM DTT, and 100 mM trisodium citrate at pH 5.5 in a black-walled, black-bottom 96-well plate (Corning). Lysates (or lysis buffer alone as a background control) were incubated for 2 hr at 37°C before reading on a fluorescence plate reader (BMG LABTECH) at excitation 360 nm, emission 460 nm with gain adjusted as necessary. Data are presented as background-corrected as relative fluorescence units.</p></sec><sec id="s4-13"><title>Immunohistochemistry</title><p>Brains from 12-month-old male and female <italic>App<sup>Wt/Wt</sup>Cst7<sup>+/+</sup></italic>, <italic>App<sup>NL-G-F</sup>Cst7<sup>+/+</sup>,</italic> and <italic>App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> mice were isolated by terminally anaesthetising with 3% isoflurane (33.3% O<sub>2</sub> and 66.6% N<sub>2</sub>O) and transcardial perfusion with ice-cold DEPC-treated 0.9% NaCl, 0.4% trisodium citrate. Brains were immediately separated down the midline then the left hemisphere placed into ice-cold 10% neutral buffered formalin (ThermoFisher). Hemi-brains were post-fixed for 48 hr at 4°C before processing for paraffin embedding. For fluorescence immunostaining used to investigate microglial and lysosomal burden, 6 μm sagittal sections were deparaffinised with 2×10 min xylene before rehydration in subsequent changes of 100%, 90%, and 70% ethanol (all 5 min). Sections were rinsed in dH<sub>2</sub>O before antigen retrieval in 10 mM TrisEDTA pH 9 (30 min at 95°C). Next, sections were rinsed and incubated with primary antibody (<xref ref-type="table" rid="table3">Table 3</xref>) in PBS, 1% BSA (Merck), 0.3% Triton-X (Merck) at 4°C overnight. Sections were washed in PBS, 0.1% Tween-20 (Merck) 3×5 min before incubation with secondary antibodies (<xref ref-type="table" rid="table3">Table 3</xref>) in PBS, 0.1% Tween-20 (Merck), 1% BSA (Merck) at RT for 1 hr. Sections were washed again, incubated in TrueBlack Lipofuscin Autofluorescence Quencher (1:300 in 70% ethanol, Biotium) for 1 min, washed again in PBS, and rinsed in dH<sub>2</sub>O before mounting with Fluorescence Mounting Medium (Dako). For synaptophysin staining, Thioflavin S (Merck) was added 1:200 for 5 min before mounting. Slides were imaged using an AxioImager D2 microscope (Zeiss) with a 20× objective. For quantification, two random fields of view were taken per mouse for both cortex and hippocampus. One image was taken for subiculum. One mouse was excluded from analysis as the section taken did not contain hippocampus. To remove the influence of plaque burden on the results, images were taken of approximately equal 6E10 burden. Images were analysed using a threshold analysis with QuPath v0.3.0 (<xref ref-type="bibr" rid="bib3">Bankhead et al., 2017</xref>) and co-staining was quantified using Definiens Developer. For imaging and quantification of synaptophysin staining, five images were taken of a single plaque/image in <italic>App<sup>NL-G-F</sup></italic> brains using a 40× oil-immersion objective with five random images in plaque-free wild-type brains. Synaptophysin coverage was calculated using ImageJ auto-threshold (default settings) and intensity within <italic>vs.</italic> outwith plaque area calculated using QuPath v0.3.0 (<xref ref-type="bibr" rid="bib3">Bankhead et al., 2017</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Antibodies used for immunohistochemistry.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Antigen</th><th align="left" valign="bottom">Type</th><th align="left" valign="bottom">Species (raised)</th><th align="left" valign="bottom">Supplier</th><th align="left" valign="bottom">Cat number</th><th align="left" valign="bottom">Stock concentration (mg/mL)</th><th align="left" valign="bottom">Dilution</th></tr></thead><tbody><tr><td align="left" valign="bottom">IBA1</td><td align="left" valign="bottom">Primary</td><td align="left" valign="bottom">Rabbit</td><td align="left" valign="bottom">Wako</td><td align="char" char="ndash" valign="bottom">019-19741</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">1:2000</td></tr><tr><td align="left" valign="bottom">Aβ (6E10)</td><td align="left" valign="bottom">Primary</td><td align="left" valign="bottom">Mouse</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">803001</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">LAMP2</td><td align="left" valign="bottom">Primary</td><td align="left" valign="bottom">Rat</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">108501</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Synaptophysin (Sy38)</td><td align="left" valign="bottom">Primary</td><td align="left" valign="bottom">Mouse</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab8049</td><td align="left" valign="bottom">Lot:1043113-1</td><td align="char" char="." valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Anti-rabbit IgG Alexa Fluor 488</td><td align="left" valign="bottom">Secondary</td><td align="left" valign="bottom">Goat</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">A-11008</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Anti-mouse IgG Alexa Fluor 555</td><td align="left" valign="bottom">Secondary</td><td align="left" valign="bottom">Donkey</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">A-31570</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Anti-rat IgG Alexa Fluor 647</td><td align="left" valign="bottom">Secondary</td><td align="left" valign="bottom">Goat</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">A-21247</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Anti-mouse Biotinylated</td><td align="left" valign="bottom">Secondary</td><td align="left" valign="bottom">Goat</td><td align="left" valign="bottom">Vector Labs</td><td align="left" valign="bottom">ba-9200</td><td align="char" char="." valign="bottom">1.5</td><td align="char" char="." valign="bottom">1:100</td></tr></tbody></table></table-wrap><p>For chromogenic 3,3'-diaminobenzidine (DAB) staining used to quantify amyloid burden, 6 μm sagittal sections were deparaffinised and rehydrated as above. Following antigen retrieval, endogenous peroxidase activity was blocked with 0.3% H<sub>2</sub>O<sub>2</sub> for 10 min and sections were blocked with 5% normal goat serum (Vector Labs) in PBS for 1 hr at RT. 6E10 primary antibody was added at 1:500 and incubated overnight at 4°C. The next day, sections were washed and stained with biotinylated anti-mouse IgG (<xref ref-type="table" rid="table3">Table 3</xref>) in PBST 1% BSA for 1 hr at RT before washing and addition of ABC Elite amplification (Vector Labs) for 30 min at RT according to the manufacturer’s instructions. After a further wash, slides were immersed in DAB solution (0.5 mg/mL DAB, 0.015% H<sub>2</sub>O<sub>2</sub> in PBS) until stain had developed. Sections were counterstained with acidified Harris Hematoxylin (Epredia), dehydrated through increasing concentrations of ethanol and xylene, and mounted with Pertex mountant (CellPath). For imaging, slides were scanned with an Axioscanner Slide Scanner (Zeiss) in brightfield at 20× magnification. Images were analysed using a threshold analysis with QuPath v0.3.0 (<xref ref-type="bibr" rid="bib3">Bankhead et al., 2017</xref>). DAB slides were stained in two batches with equal representation of groups between batches, data are presented as batch-normalised 6E10 % positive area.</p></sec><sec id="s4-14"><title><italic>In situ</italic> hybridisation</title><p><italic>In situ</italic> hybridisation was performed using RNAscope 2.5 HD Duplex Assay using slight modifications to the manufacturer’s protocol. Freshly cut (6 µm) brain tissue was baked onto slides at 60°C for 30 min before deparaffinisation (2× xylene, 5 min) and dehydration (2×100% EtOH, 1 min). Hydrogen peroxide was applied for 10 min at RT and antigen retrieval was performed for 30 min in a pre-heated (20 min) plastic Coplin jar in a 97.5°C waterbath. Sections were left at RT overnight before placing into humidity chambers and protease plus was applied for 15 min at 37°C. Probes targeting <italic>Cst7</italic> (498711-C2) and <italic>Lilrb4a</italic> (1260291-C2) were incubated for 2 hr at 40°C, amplified according to the manufacturer’s instructions, and red signal detected using RNAScope Fast Red. At this stage, antibodies raised against IBA1 and Aβ (6E10) were added as described above and the experiment continued as with fluorescence immunohistochemistry as above. RNAScope Fast Red is detectable both in brightfield and fluorescence in 555 channel. For imaging, slides were either scanned with an Axioscanner Slide Scanner (Zeiss) in brightfield at ×20 magnification or imaged in fluorescence using an AxioImager D2 microscope (Zeiss) with a ×20 objective. For quantification, two random fields of view were taken per mouse cortex. Images were analysed for <italic>Cst7/Lilrb4a</italic> coverage within/outwith plaque region using QuPath v0.3.0 (<xref ref-type="bibr" rid="bib3">Bankhead et al., 2017</xref>) to draw around 6E10+ area and co-localisation with IBA1 was analysed using MultipleColourAnalysis ImageJ plugin.</p></sec><sec id="s4-15"><title>Multiplex ELISA</title><p>Mouse cytokines from microglial supernatants were measured using MILLIPLEX multiplex assays as described previously (<xref ref-type="bibr" rid="bib44">McCulloch et al., 2022</xref>). Briefly, MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel (MCYTOMAG-70K, Merck) was used to measure GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-12(p40), IL-33, and TNF-α. In all assays, samples were assayed as single replicates and all samples, standards, and quality controls were prepared in accordance with the manufacturer’s instructions. Samples were incubated with beads on a plate for 1 hr (isotyping assay) or overnight at 4°C and washes carried out using a magnetic plate washer. Plates were analysed using a Magpix Luminex machine and Luminex xPonent software version 4.2, with a sample volume of 50 μL per well and a minimum of 50 events counted per sample.</p></sec><sec id="s4-16"><title>Randomisation and blinding</title><p>Experimenters were blinded to genotype groups throughout the study. Animals were given an experimental identifier and all samples were analysed using this coded identifier. Mice were randomly assigned to cull groups using random number generator on Microsoft Excel (which were performed in batches due to throughput for FACS) with stratification for experimental group. Order of MeX04 injection and subsequent mouse termination and tissue collection was randomised by random number generator using Microsoft Excel. Data was unblinded for analysis after experimental work was complete. There were no specific inclusion/exclusion criteria. However, mice were excluded from IHC analysis in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig6">6</xref> due to attrition (tissue sections were not obtainable of the specific regions required). Power calculations (α=0.05, power = 0.8) based on the primary outcome of 50% effect size on <italic>App<sup>NL-G-F</sup></italic> vs<italic>. App<sup>NL-G-F</sup>Cst7<sup>-/-</sup></italic> %MeX04+ microglia demonstrated n=12 would be sufficient for our study.</p></sec><sec id="s4-17"><title>Statistical analyses</title><p>Data are presented as mean values + standard error of the mean (SEM). Levels of significance were p&lt;0.05 (*), p&lt;0.01 (**), p&lt;0.001 (***). In all figures, replicates (defined by n) were biological replicates. Statistical analyses were carried out using GraphPad Prism (version 9). For RNASeq data, statistical significance was calculated using DESeq2 R package (<xref ref-type="bibr" rid="bib40">Love et al., 2014</xref>). Immunohistochemistry, qPCR, cathepsin activity, and cytokine secretion were analysed with a two-way ANOVA followed by Tukey’s or Sidak’s post hoc comparisons, unpaired Student’s t-test, or mixed effects modelling. Live-imaging data were analysed by area under the curve followed by Student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons test. Transformations were applied where necessary. Graphs and figures were created with GraphPad Prism (version 9), VolcaNoseR (<xref ref-type="bibr" rid="bib16">Goedhart and Luijsterburg, 2020</xref>), DeepVenn (<xref ref-type="bibr" rid="bib28">Hulsen, 2022</xref>), and <ext-link ext-link-type="uri" xlink:href="http://www.biorender.com">BioRender.com</ext-link>.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con10"><p>Methodology, Project administration</p></fn><fn fn-type="con" id="con11"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con14"><p>Resources, Supervision, Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing – original draft, Project administration, Writing – review and editing, Investigation, Resources</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Use of human tissue for synaptoneurosome experiments above was reviewed and approved by the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee, AMREC (approval number 15-HV-016; ACCORD is the Academic and Clinical Central Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian). The Edinburgh Brain Bank is a Medical Research Council funded facility with research ethics committee (REC) approval (11/ES/0022).</p></fn><fn fn-type="other"><p>All animal experiments were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 and approved by the United Kingdom Home Office and the local Animal Ethical Review Group, University of Edinburgh.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85279-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data obtained and reanalysed in <xref ref-type="fig" rid="fig1">Figure 1</xref> was obtained from published manuscripts. All data have been deposited in GEO: GSE89482 (<xref ref-type="bibr" rid="bib58">Srinivasan et al., 2020</xref>), GSE65067 (<xref ref-type="bibr" rid="bib68">Wang et al., 2015</xref>), GSE74615 (<xref ref-type="bibr" rid="bib47">Orre et al., 2014</xref>), GSE117646 (<xref ref-type="bibr" rid="bib30">Kang et al., 2018</xref>), GSE203202 (<xref ref-type="bibr" rid="bib19">Guillot-Sestier et al., 2021</xref>), GSE127893 (<xref ref-type="bibr" rid="bib55">Sala Frigerio et al., 2019</xref>). Newly generated data that support the findings of this study are uploaded to ArrayExpress (Accession ID:E-MTAB-13360).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>MJ</given-names></name><name><surname>Lefevre</surname><given-names>L</given-names></name><name><surname>Szymkowiak</surname><given-names>S</given-names></name><name><surname>Drak</surname><given-names>A</given-names></name><name><surname>McCulloch</surname><given-names>L</given-names></name><name><surname>Tzioras</surname><given-names>M</given-names></name><name><surname>Barrington</surname><given-names>J</given-names></name><name><surname>Dando</surname><given-names>OR</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Mohammad</surname><given-names>M</given-names></name><name><surname>Sasaguri</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Saido</surname><given-names>TC</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>McColl</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>RNA-seq to investigate sex-dependent changes in microglia in Cst7 knockout mice crossed with a mouse model of amyloid-driven Alzheimer's Disease</data-title><source>ArrayExpress</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-13360">E-MTAB-13360</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Expression data from WT and TREM2 deficient microglia in a mouse model of Alzheimer's disease</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65067">GSE65067</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>B</given-names></name><name><surname>Srinivasan</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Gene Expression in Cx3cr1-GFP+ Cells in PS2APP Alzheimer's Disease mice</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89482">GSE89482</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Orre</surname><given-names>M</given-names></name><name><surname>Kamphuis</surname><given-names>W</given-names></name><name><surname>Bossers</surname><given-names>K</given-names></name><name><surname>Hol</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Acutely isolated murine cortical astrocytes and microglia: Alzheimer's disease vs wildtype</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74615">GSE74615</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Fryer</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117646">GSE117646</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset6"><person-group person-group-type="author"><name><surname>Mela</surname><given-names>V</given-names></name><name><surname>Lynch</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Sex-related differences in Alzheimer's disease</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203202">GSE203202</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset7"><person-group person-group-type="author"><name><surname>Sala Frigerio</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>The major risk factors for Alzheimer's disease: Age, Sex and Genes, modulate the microglia response to Aβ plaques</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE127893">GSE127893</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work is supported by the UK Dementia Research Institute which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK and the Leducq Foundation Transatlantic Network of Excellence, Stroke IMPaCT (19CVD01). For the purpose of open access, the author has applied a CC-BY public copyright license to any Author Accepted Manuscript version arising from this submission. We would like to thank the QMRI Flow Cytometry &amp; Cell Sorting Facility at The University of Edinburgh for assistance with FACS studies, the Shared University Research Facilities (SuRF) Histology facility at The University of Edinburgh for assistance with processing, sectioning, and slide-scanning brains, Dr Daniel Soong at The MRC Centre for Reproductive Health, University of Edinburgh for his assistance with image analysis, and Prof. Siddharthan Chandran at The University of Edinburgh for providing the SH-SY5Y cell line.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexa</surname><given-names>A</given-names></name><name><surname>Rahnenführer</surname><given-names>J</given-names></name><name><surname>Lengauer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Improved scoring of functional groups from gene expression data by decorrelating GO graph structure</article-title><source>Bioinformatics</source><volume>22</volume><fpage>1600</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btl140</pub-id><pub-id pub-id-type="pmid">16606683</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altmann</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Henderson</surname><given-names>VW</given-names></name><name><surname>Greicius</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sex modifies the APOE-related risk of developing Alzheimer disease</article-title><source>Annals of Neurology</source><volume>75</volume><fpage>563</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1002/ana.24135</pub-id><pub-id pub-id-type="pmid">24623176</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bankhead</surname><given-names>P</given-names></name><name><surname>Loughrey</surname><given-names>MB</given-names></name><name><surname>Fernández</surname><given-names>JA</given-names></name><name><surname>Dombrowski</surname><given-names>Y</given-names></name><name><surname>McArt</surname><given-names>DG</given-names></name><name><surname>Dunne</surname><given-names>PD</given-names></name><name><surname>McQuaid</surname><given-names>S</given-names></name><name><surname>Gray</surname><given-names>RT</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Coleman</surname><given-names>HG</given-names></name><name><surname>James</surname><given-names>JA</given-names></name><name><surname>Salto-Tellez</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>QuPath: Open source software for digital pathology image analysis</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>16878</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-17204-5</pub-id><pub-id pub-id-type="pmid">29203879</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasi</surname><given-names>E</given-names></name><name><surname>Barluzzi</surname><given-names>R</given-names></name><name><surname>Bocchini</surname><given-names>V</given-names></name><name><surname>Mazzolla</surname><given-names>R</given-names></name><name><surname>Bistoni</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus</article-title><source>Journal of Neuroimmunology</source><volume>27</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/0165-5728(90)90073-v</pub-id><pub-id pub-id-type="pmid">2110186</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WT</given-names></name><name><surname>Lu</surname><given-names>A</given-names></name><name><surname>Craessaerts</surname><given-names>K</given-names></name><name><surname>Pavie</surname><given-names>B</given-names></name><name><surname>Sala Frigerio</surname><given-names>C</given-names></name><name><surname>Corthout</surname><given-names>N</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Laláková</surname><given-names>J</given-names></name><name><surname>Kühnemund</surname><given-names>M</given-names></name><name><surname>Voytyuk</surname><given-names>I</given-names></name><name><surname>Wolfs</surname><given-names>L</given-names></name><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Salta</surname><given-names>E</given-names></name><name><surname>Balusu</surname><given-names>S</given-names></name><name><surname>Snellinx</surname><given-names>A</given-names></name><name><surname>Munck</surname><given-names>S</given-names></name><name><surname>Jurek</surname><given-names>A</given-names></name><name><surname>Fernandez Navarro</surname><given-names>J</given-names></name><name><surname>Saido</surname><given-names>TC</given-names></name><name><surname>Huitinga</surname><given-names>I</given-names></name><name><surname>Lundeberg</surname><given-names>J</given-names></name><name><surname>Fiers</surname><given-names>M</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Spatial transcriptomics and in situ sequencing to study alzheimer’s disease</article-title><source>Cell</source><volume>182</volume><fpage>976</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.038</pub-id><pub-id pub-id-type="pmid">32702314</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Butovsky</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Microglia function in the central nervous system during health and neurodegeneration</article-title><source>Annual Review of Immunology</source><volume>35</volume><fpage>441</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-051116-052358</pub-id><pub-id pub-id-type="pmid">28226226</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Alvarez-Jarreta</surname><given-names>J</given-names></name><name><surname>Amode</surname><given-names>MR</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Austine-Orimoloye</surname><given-names>O</given-names></name><name><surname>Azov</surname><given-names>AG</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Bennett</surname><given-names>R</given-names></name><name><surname>Berry</surname><given-names>A</given-names></name><name><surname>Bhai</surname><given-names>J</given-names></name><name><surname>Bignell</surname><given-names>A</given-names></name><name><surname>Billis</surname><given-names>K</given-names></name><name><surname>Boddu</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>L</given-names></name><name><surname>Charkhchi</surname><given-names>M</given-names></name><name><surname>Cummins</surname><given-names>C</given-names></name><name><surname>Da Rin Fioretto</surname><given-names>L</given-names></name><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Dodiya</surname><given-names>K</given-names></name><name><surname>Donaldson</surname><given-names>S</given-names></name><name><surname>El Houdaigui</surname><given-names>B</given-names></name><name><surname>El Naboulsi</surname><given-names>T</given-names></name><name><surname>Fatima</surname><given-names>R</given-names></name><name><surname>Giron</surname><given-names>CG</given-names></name><name><surname>Genez</surname><given-names>T</given-names></name><name><surname>Martinez</surname><given-names>JG</given-names></name><name><surname>Guijarro-Clarke</surname><given-names>C</given-names></name><name><surname>Gymer</surname><given-names>A</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><name><surname>Hollis</surname><given-names>Z</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Juettemann</surname><given-names>T</given-names></name><name><surname>Kaikala</surname><given-names>V</given-names></name><name><surname>Kay</surname><given-names>M</given-names></name><name><surname>Lavidas</surname><given-names>I</given-names></name><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Lemos</surname><given-names>D</given-names></name><name><surname>Marugán</surname><given-names>JC</given-names></name><name><surname>Mohanan</surname><given-names>S</given-names></name><name><surname>Mushtaq</surname><given-names>A</given-names></name><name><surname>Naven</surname><given-names>M</given-names></name><name><surname>Ogeh</surname><given-names>DN</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Parton</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>M</given-names></name><name><surname>Piližota</surname><given-names>I</given-names></name><name><surname>Prosovetskaia</surname><given-names>I</given-names></name><name><surname>Sakthivel</surname><given-names>MP</given-names></name><name><surname>Salam</surname><given-names>AIA</given-names></name><name><surname>Schmitt</surname><given-names>BM</given-names></name><name><surname>Schuilenburg</surname><given-names>H</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name><name><surname>Pérez-Silva</surname><given-names>JG</given-names></name><name><surname>Stark</surname><given-names>W</given-names></name><name><surname>Steed</surname><given-names>E</given-names></name><name><surname>Sutinen</surname><given-names>K</given-names></name><name><surname>Sukumaran</surname><given-names>R</given-names></name><name><surname>Sumathipala</surname><given-names>D</given-names></name><name><surname>Suner</surname><given-names>MM</given-names></name><name><surname>Szpak</surname><given-names>M</given-names></name><name><surname>Thormann</surname><given-names>A</given-names></name><name><surname>Tricomi</surname><given-names>FF</given-names></name><name><surname>Urbina-Gómez</surname><given-names>D</given-names></name><name><surname>Veidenberg</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>TA</given-names></name><name><surname>Walts</surname><given-names>B</given-names></name><name><surname>Willhoft</surname><given-names>N</given-names></name><name><surname>Winterbottom</surname><given-names>A</given-names></name><name><surname>Wass</surname><given-names>E</given-names></name><name><surname>Chakiachvili</surname><given-names>M</given-names></name><name><surname>Flint</surname><given-names>B</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Giorgetti</surname><given-names>S</given-names></name><name><surname>Haggerty</surname><given-names>L</given-names></name><name><surname>Hunt</surname><given-names>SE</given-names></name><name><surname>IIsley</surname><given-names>GR</given-names></name><name><surname>Loveland</surname><given-names>JE</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Moore</surname><given-names>B</given-names></name><name><surname>Mudge</surname><given-names>JM</given-names></name><name><surname>Muffato</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Tate</surname><given-names>J</given-names></name><name><surname>Thybert</surname><given-names>D</given-names></name><name><surname>Trevanion</surname><given-names>SJ</given-names></name><name><surname>Dyer</surname><given-names>S</given-names></name><name><surname>Harrison</surname><given-names>PW</given-names></name><name><surname>Howe</surname><given-names>KL</given-names></name><name><surname>Yates</surname><given-names>AD</given-names></name><name><surname>Zerbino</surname><given-names>DR</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ensembl 2022</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D988</fpage><lpage>D995</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1049</pub-id><pub-id pub-id-type="pmid">34791404</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deczkowska</surname><given-names>A</given-names></name><name><surname>Keren-Shaul</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>A</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Disease-associated microglia: A universal immune sensor of neurodegeneration</article-title><source>Cell</source><volume>173</volume><fpage>1073</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.05.003</pub-id><pub-id pub-id-type="pmid">29775591</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d’Errico</surname><given-names>P</given-names></name><name><surname>Ziegler-Waldkirch</surname><given-names>S</given-names></name><name><surname>Aires</surname><given-names>V</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Mezö</surname><given-names>C</given-names></name><name><surname>Erny</surname><given-names>D</given-names></name><name><surname>Monasor</surname><given-names>LS</given-names></name><name><surname>Liebscher</surname><given-names>S</given-names></name><name><surname>Ravi</surname><given-names>VM</given-names></name><name><surname>Joseph</surname><given-names>K</given-names></name><name><surname>Schnell</surname><given-names>O</given-names></name><name><surname>Kierdorf</surname><given-names>K</given-names></name><name><surname>Staszewski</surname><given-names>O</given-names></name><name><surname>Tahirovic</surname><given-names>S</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Meyer-Luehmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Microglia contribute to the propagation of Aβ into unaffected brain tissue</article-title><source>Nature Neuroscience</source><volume>25</volume><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/s41593-021-00951-0</pub-id><pub-id pub-id-type="pmid">34811521</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeTure</surname><given-names>MA</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The neuropathological diagnosis of Alzheimer’s disease</article-title><source>Molecular Neurodegeneration</source><volume>14</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmid">31375134</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Novick</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kaplanski</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interleukin-18 and IL-18 binding protein</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>289</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00289</pub-id><pub-id pub-id-type="pmid">24115947</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gail Canter</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ashley Watson</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>CG</given-names></name><name><surname>Abdurrob</surname><given-names>F</given-names></name><name><surname>Bousleiman</surname><given-names>SM</given-names></name><name><surname>Young</surname><given-names>JZ</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Delalle</surname><given-names>I</given-names></name><name><surname>Chung</surname><given-names>K</given-names></name><name><surname>Tsai</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice</article-title><source>Communications Biology</source><volume>2</volume><elocation-id>360</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-019-0599-8</pub-id><pub-id pub-id-type="pmid">31602409</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamache</surname><given-names>J</given-names></name><name><surname>Yun</surname><given-names>Y</given-names></name><name><surname>Chiba-Falek</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sex-dependent effect of <italic>APOE</italic> on Alzheimer’s disease and other age-related neurodegenerative disorders</article-title><source>Disease Models &amp; Mechanisms</source><volume>13</volume><elocation-id>dmm045211</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.045211</pub-id><pub-id pub-id-type="pmid">32859588</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerrits</surname><given-names>E</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><name><surname>Kooistra</surname><given-names>SM</given-names></name><name><surname>Woodbury</surname><given-names>ME</given-names></name><name><surname>Vermeiren</surname><given-names>Y</given-names></name><name><surname>Lambourne</surname><given-names>M</given-names></name><name><surname>Mulder</surname><given-names>J</given-names></name><name><surname>Kummer</surname><given-names>M</given-names></name><name><surname>Möller</surname><given-names>T</given-names></name><name><surname>Biber</surname><given-names>K</given-names></name><name><surname>den Dunnen</surname><given-names>W</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Eggen</surname><given-names>BJL</given-names></name><name><surname>Boddeke</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease</article-title><source>Acta Neuropathologica</source><volume>141</volume><fpage>681</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s00401-021-02263-w</pub-id><pub-id pub-id-type="pmid">33609158</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedhart</surname><given-names>J</given-names></name><name><surname>Luijsterburg</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>20560</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-76603-3</pub-id><pub-id pub-id-type="pmid">33239692</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabert</surname><given-names>K</given-names></name><name><surname>McColl</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Isolation and phenotyping of adult mouse microglial cells</article-title><source>Methods in Molecular Biology</source><volume>1784</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7837-3_7</pub-id><pub-id pub-id-type="pmid">29761389</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubman</surname><given-names>A</given-names></name><name><surname>Choo</surname><given-names>XY</given-names></name><name><surname>Chew</surname><given-names>G</given-names></name><name><surname>Ouyang</surname><given-names>JF</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Croft</surname><given-names>NP</given-names></name><name><surname>Rossello</surname><given-names>FJ</given-names></name><name><surname>Simmons</surname><given-names>R</given-names></name><name><surname>Buckberry</surname><given-names>S</given-names></name><name><surname>Landin</surname><given-names>DV</given-names></name><name><surname>Pflueger</surname><given-names>J</given-names></name><name><surname>Vandekolk</surname><given-names>TH</given-names></name><name><surname>Abay</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Larcombe</surname><given-names>M</given-names></name><name><surname>Haynes</surname><given-names>JM</given-names></name><name><surname>McLean</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Chai</surname><given-names>SY</given-names></name><name><surname>Wilson</surname><given-names>T</given-names></name><name><surname>Lister</surname><given-names>R</given-names></name><name><surname>Pouton</surname><given-names>CW</given-names></name><name><surname>Purcell</surname><given-names>AW</given-names></name><name><surname>Rackham</surname><given-names>OJL</given-names></name><name><surname>Petretto</surname><given-names>E</given-names></name><name><surname>Polo</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transcriptional signature in microglia associated with Aβ plaque phagocytosis</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3015</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23111-1</pub-id><pub-id pub-id-type="pmid">34021136</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillot-Sestier</surname><given-names>MV</given-names></name><name><surname>Araiz</surname><given-names>AR</given-names></name><name><surname>Mela</surname><given-names>V</given-names></name><name><surname>Gaban</surname><given-names>AS</given-names></name><name><surname>O’Neill</surname><given-names>E</given-names></name><name><surname>Joshi</surname><given-names>L</given-names></name><name><surname>Chouchani</surname><given-names>ET</given-names></name><name><surname>Mills</surname><given-names>EL</given-names></name><name><surname>Lynch</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microglial metabolism is a pivotal factor in sexual dimorphism in Alzheimer’s disease</article-title><source>Communications Biology</source><volume>4</volume><elocation-id>711</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-02259-y</pub-id><pub-id pub-id-type="pmid">34112929</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guneykaya</surname><given-names>D</given-names></name><name><surname>Ivanov</surname><given-names>A</given-names></name><name><surname>Hernandez</surname><given-names>DP</given-names></name><name><surname>Haage</surname><given-names>V</given-names></name><name><surname>Wojtas</surname><given-names>B</given-names></name><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Maricos</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>P</given-names></name><name><surname>Buonfiglioli</surname><given-names>A</given-names></name><name><surname>Gielniewski</surname><given-names>B</given-names></name><name><surname>Ochocka</surname><given-names>N</given-names></name><name><surname>Cömert</surname><given-names>C</given-names></name><name><surname>Friedrich</surname><given-names>C</given-names></name><name><surname>Artiles</surname><given-names>LS</given-names></name><name><surname>Kaminska</surname><given-names>B</given-names></name><name><surname>Mertins</surname><given-names>P</given-names></name><name><surname>Beule</surname><given-names>D</given-names></name><name><surname>Kettenmann</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transcriptional and translational differences of microglia from male and female brains</article-title><source>Cell Reports</source><volume>24</volume><fpage>2773</fpage><lpage>2783</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.001</pub-id><pub-id pub-id-type="pmid">30184509</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Colbert</surname><given-names>JD</given-names></name><name><surname>Schuettelkopf</surname><given-names>AW</given-names></name><name><surname>Watts</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis</article-title><source>The EMBO Journal</source><volume>27</volume><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601979</pub-id><pub-id pub-id-type="pmid">18256700</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>DV</given-names></name><name><surname>Hanson</surname><given-names>JE</given-names></name><name><surname>Sheng</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Microglia in Alzheimer’s disease</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1083/jcb.201709069</pub-id><pub-id pub-id-type="pmid">29196460</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Kummer</surname><given-names>MP</given-names></name><name><surname>Stutz</surname><given-names>A</given-names></name><name><surname>Delekate</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Vieira-Saecker</surname><given-names>A</given-names></name><name><surname>Griep</surname><given-names>A</given-names></name><name><surname>Axt</surname><given-names>D</given-names></name><name><surname>Remus</surname><given-names>A</given-names></name><name><surname>Tzeng</surname><given-names>TC</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Halle</surname><given-names>A</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Golenbock</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice</article-title><source>Nature</source><volume>493</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nature11729</pub-id><pub-id pub-id-type="pmid">23254930</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoghooghi</surname><given-names>V</given-names></name><name><surname>Palmer</surname><given-names>AL</given-names></name><name><surname>Frederick</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Merkens</surname><given-names>JE</given-names></name><name><surname>Balakrishnan</surname><given-names>A</given-names></name><name><surname>Finlay</surname><given-names>TM</given-names></name><name><surname>Grubb</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>E</given-names></name><name><surname>Gordon</surname><given-names>P</given-names></name><name><surname>Jirik</surname><given-names>FR</given-names></name><name><surname>Nguyen</surname><given-names>MD</given-names></name><name><surname>Schuurmans</surname><given-names>C</given-names></name><name><surname>Visser</surname><given-names>F</given-names></name><name><surname>Dunn</surname><given-names>SE</given-names></name><name><surname>Ousman</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cystatin C plays a sex-dependent detrimental role in experimental autoimmune encephalomyelitis</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108236</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108236</pub-id><pub-id pub-id-type="pmid">33027652</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Beja-Glasser</surname><given-names>VF</given-names></name><name><surname>Nfonoyim</surname><given-names>BM</given-names></name><name><surname>Frouin</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ramakrishnan</surname><given-names>S</given-names></name><name><surname>Merry</surname><given-names>KM</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Lemere</surname><given-names>CA</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complement and microglia mediate early synapse loss in Alzheimer mouse models</article-title><source>Science</source><volume>352</volume><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1126/science.aad8373</pub-id><pub-id pub-id-type="pmid">27033548</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Spusta</surname><given-names>SC</given-names></name><name><surname>Niemi</surname><given-names>EC</given-names></name><name><surname>Yenari</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>MC</given-names></name><name><surname>Seaman</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia</article-title><source>Journal of Neurochemistry</source><volume>109</volume><fpage>1144</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06042.x</pub-id><pub-id pub-id-type="pmid">19302484</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Happonen</surname><given-names>KE</given-names></name><name><surname>Burrola</surname><given-names>PG</given-names></name><name><surname>O’Connor</surname><given-names>C</given-names></name><name><surname>Hah</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Nimmerjahn</surname><given-names>A</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microglia use TAM receptors to detect and engulf amyloid β plaques</article-title><source>Nature Immunology</source><volume>22</volume><fpage>586</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00913-5</pub-id><pub-id pub-id-type="pmid">33859405</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Hulsen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>DeepVenn -- a web application for the creation of area-proportional Venn diagrams using the deep learning framework Tensorflow.js</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.48550/arXiv.2210.04597">https://doi.org/10.48550/arXiv.2210.04597</ext-link></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurme</surname><given-names>M</given-names></name><name><surname>Santtila</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes</article-title><source>European Journal of Immunology</source><volume>28</volume><fpage>2598</fpage><lpage>2602</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199808)28:08&lt;2598::AID-IMMU2598&gt;3.0.CO;2-K</pub-id><pub-id pub-id-type="pmid">9710237</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SS</given-names></name><name><surname>Ebbert</surname><given-names>MTW</given-names></name><name><surname>Baker</surname><given-names>KE</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sens</surname><given-names>JP</given-names></name><name><surname>Kocher</surname><given-names>JP</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Fryer</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>2235</fpage><lpage>2245</lpage><pub-id pub-id-type="doi">10.1084/jem.20180653</pub-id><pub-id pub-id-type="pmid">30082275</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren-Shaul</surname><given-names>H</given-names></name><name><surname>Spinrad</surname><given-names>A</given-names></name><name><surname>Weiner</surname><given-names>A</given-names></name><name><surname>Matcovitch-Natan</surname><given-names>O</given-names></name><name><surname>Dvir-Szternfeld</surname><given-names>R</given-names></name><name><surname>Ulland</surname><given-names>TK</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Baruch</surname><given-names>K</given-names></name><name><surname>Lara-Astaiso</surname><given-names>D</given-names></name><name><surname>Toth</surname><given-names>B</given-names></name><name><surname>Itzkovitz</surname><given-names>S</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A unique microglia type associated with restricting development of Alzheimer’s disease</article-title><source>Cell</source><volume>169</volume><fpage>1276</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.018</pub-id><pub-id pub-id-type="pmid">28602351</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiani Shabestari</surname><given-names>S</given-names></name><name><surname>Morabito</surname><given-names>S</given-names></name><name><surname>Danhash</surname><given-names>EP</given-names></name><name><surname>McQuade</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>JR</given-names></name><name><surname>Miyoshi</surname><given-names>E</given-names></name><name><surname>Chadarevian</surname><given-names>JP</given-names></name><name><surname>Claes</surname><given-names>C</given-names></name><name><surname>Coburn</surname><given-names>MA</given-names></name><name><surname>Hasselmann</surname><given-names>J</given-names></name><name><surname>Hidalgo</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>KN</given-names></name><name><surname>Martini</surname><given-names>AC</given-names></name><name><surname>Chang Rothermich</surname><given-names>W</given-names></name><name><surname>Pascual</surname><given-names>J</given-names></name><name><surname>Head</surname><given-names>E</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name><name><surname>Pridans</surname><given-names>C</given-names></name><name><surname>Davtyan</surname><given-names>H</given-names></name><name><surname>Swarup</surname><given-names>V</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice</article-title><source>Cell Reports</source><volume>39</volume><elocation-id>110961</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110961</pub-id><pub-id pub-id-type="pmid">35705056</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinberger</surname><given-names>G</given-names></name><name><surname>Yamanishi</surname><given-names>Y</given-names></name><name><surname>Suárez-Calvet</surname><given-names>M</given-names></name><name><surname>Czirr</surname><given-names>E</given-names></name><name><surname>Lohmann</surname><given-names>E</given-names></name><name><surname>Cuyvers</surname><given-names>E</given-names></name><name><surname>Struyfs</surname><given-names>H</given-names></name><name><surname>Pettkus</surname><given-names>N</given-names></name><name><surname>Wenninger-Weinzierl</surname><given-names>A</given-names></name><name><surname>Mazaheri</surname><given-names>F</given-names></name><name><surname>Tahirovic</surname><given-names>S</given-names></name><name><surname>Lleó</surname><given-names>A</given-names></name><name><surname>Alcolea</surname><given-names>D</given-names></name><name><surname>Fortea</surname><given-names>J</given-names></name><name><surname>Willem</surname><given-names>M</given-names></name><name><surname>Lammich</surname><given-names>S</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Sánchez-Valle</surname><given-names>R</given-names></name><name><surname>Antonell</surname><given-names>A</given-names></name><name><surname>Ramirez</surname><given-names>A</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>JJ</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Demirtas-Tatlidede</surname><given-names>A</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Gurvit</surname><given-names>H</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis</article-title><source>Science Translational Medicine</source><volume>6</volume><elocation-id>243ra86</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3009093</pub-id><pub-id pub-id-type="pmid">24990881</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>L</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Do microglial sex differences contribute to sex differences in neurodegenerative diseases?</article-title><source>Trends in Molecular Medicine</source><volume>25</volume><fpage>741</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2019.05.001</pub-id><pub-id pub-id-type="pmid">31171460</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasemann</surname><given-names>S</given-names></name><name><surname>Madore</surname><given-names>C</given-names></name><name><surname>Cialic</surname><given-names>R</given-names></name><name><surname>Baufeld</surname><given-names>C</given-names></name><name><surname>Calcagno</surname><given-names>N</given-names></name><name><surname>El Fatimy</surname><given-names>R</given-names></name><name><surname>Beckers</surname><given-names>L</given-names></name><name><surname>O’Loughlin</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Fanek</surname><given-names>Z</given-names></name><name><surname>Greco</surname><given-names>DJ</given-names></name><name><surname>Smith</surname><given-names>ST</given-names></name><name><surname>Tweet</surname><given-names>G</given-names></name><name><surname>Humulock</surname><given-names>Z</given-names></name><name><surname>Zrzavy</surname><given-names>T</given-names></name><name><surname>Conde-Sanroman</surname><given-names>P</given-names></name><name><surname>Gacias</surname><given-names>M</given-names></name><name><surname>Weng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Tjon</surname><given-names>E</given-names></name><name><surname>Mazaheri</surname><given-names>F</given-names></name><name><surname>Hartmann</surname><given-names>K</given-names></name><name><surname>Madi</surname><given-names>A</given-names></name><name><surname>Ulrich</surname><given-names>JD</given-names></name><name><surname>Glatzel</surname><given-names>M</given-names></name><name><surname>Worthmann</surname><given-names>A</given-names></name><name><surname>Heeren</surname><given-names>J</given-names></name><name><surname>Budnik</surname><given-names>B</given-names></name><name><surname>Lemere</surname><given-names>C</given-names></name><name><surname>Ikezu</surname><given-names>T</given-names></name><name><surname>Heppner</surname><given-names>FL</given-names></name><name><surname>Litvak</surname><given-names>V</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Butovsky</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases</article-title><source>Immunity</source><volume>47</volume><fpage>566</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.08.008</pub-id><pub-id pub-id-type="pmid">28930663</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung-Tack</surname><given-names>J</given-names></name><name><surname>Tavera</surname><given-names>C</given-names></name><name><surname>Gensac</surname><given-names>MC</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Colle</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg</article-title><source>Experimental Cell Research</source><volume>188</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/0014-4827(90)90272-c</pub-id><pub-id pub-id-type="pmid">2158459</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ikenaka</surname><given-names>K</given-names></name><name><surname>Fan</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Disinhibition of cathepsin C caused by cystatin F deficiency aggravates the demyelination in a cuprizone model</article-title><source>Frontiers in Molecular Neuroscience</source><volume>9</volume><elocation-id>152</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2016.00152</pub-id><pub-id pub-id-type="pmid">28066178</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzo</surname><given-names>JP</given-names></name><name><surname>Petanceska</surname><given-names>SS</given-names></name><name><surname>Devi</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Neurotrophic factors regulate cathepsin S in macrophages and microglia: A role in the degradation of myelin basic protein and amyloid beta peptide</article-title><source>Molecular Medicine</source><volume>5</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">10390549</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Exploring sex-related differences in microglia may be a game-changer in precision medicine</article-title><source>Frontiers in Aging Neuroscience</source><volume>14</volume><elocation-id>868448</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2022.868448</pub-id><pub-id pub-id-type="pmid">35431903</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathys</surname><given-names>H</given-names></name><name><surname>Davila-Velderrain</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Mohammadi</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>JZ</given-names></name><name><surname>Menon</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Abdurrob</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Martorell</surname><given-names>AJ</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Hafler</surname><given-names>BP</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Tsai</surname><given-names>L-H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Author correction: Single-cell transcriptomic analysis of Alzheimer’s disease</article-title><source>Nature</source><volume>571</volume><fpage>332</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1329-6</pub-id><pub-id pub-id-type="pmid">31209304</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>SP</given-names></name><name><surname>McMillan</surname><given-names>SJ</given-names></name><name><surname>Colbert</surname><given-names>JD</given-names></name><name><surname>Lawrence</surname><given-names>RA</given-names></name><name><surname>Watts</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cystatin F ensures eosinophil survival by regulating granule biogenesis</article-title><source>Immunity</source><volume>44</volume><fpage>795</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.03.003</pub-id><pub-id pub-id-type="pmid">27067058</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCulloch</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>AJ</given-names></name><name><surname>Malbon</surname><given-names>A</given-names></name><name><surname>Daniels</surname><given-names>MJD</given-names></name><name><surname>Younas</surname><given-names>M</given-names></name><name><surname>Grainger</surname><given-names>JR</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>McColl</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Treatment with IgM-enriched intravenous immunoglobulins enhances clearance of stroke-associated bacterial lung infection</article-title><source>Immunology</source><volume>167</volume><fpage>558</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1111/imm.13553</pub-id><pub-id pub-id-type="pmid">35881080</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuvolone</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>N</given-names></name><name><surname>Miele</surname><given-names>G</given-names></name><name><surname>Sorce</surname><given-names>S</given-names></name><name><surname>Moos</surname><given-names>R</given-names></name><name><surname>Schori</surname><given-names>C</given-names></name><name><surname>Beerli</surname><given-names>RR</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Saudan</surname><given-names>P</given-names></name><name><surname>Dietmeier</surname><given-names>K</given-names></name><name><surname>Lachmann</surname><given-names>I</given-names></name><name><surname>Linnebank</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Kallweit</surname><given-names>U</given-names></name><name><surname>Kana</surname><given-names>V</given-names></name><name><surname>Rushing</surname><given-names>EJ</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cystatin F is a biomarker of prion pathogenesis in mice</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0171923</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0171923</pub-id><pub-id pub-id-type="pmid">28178353</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ofengeim</surname><given-names>D</given-names></name><name><surname>Mazzitelli</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>DeWitt</surname><given-names>JP</given-names></name><name><surname>Mifflin</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>C</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Adiconis</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Kelliher</surname><given-names>MA</given-names></name><name><surname>Levin</surname><given-names>JZ</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease</article-title><source>PNAS</source><volume>114</volume><fpage>E8788</fpage><lpage>E8797</lpage><pub-id pub-id-type="doi">10.1073/pnas.1714175114</pub-id><pub-id pub-id-type="pmid">28904096</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orre</surname><given-names>M</given-names></name><name><surname>Kamphuis</surname><given-names>W</given-names></name><name><surname>Osborn</surname><given-names>LM</given-names></name><name><surname>Jansen</surname><given-names>AHP</given-names></name><name><surname>Kooijman</surname><given-names>L</given-names></name><name><surname>Bossers</surname><given-names>K</given-names></name><name><surname>Hol</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction</article-title><source>Neurobiology of Aging</source><volume>35</volume><fpage>2746</fpage><lpage>2760</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.06.004</pub-id><pub-id pub-id-type="pmid">25002035</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percie du Sert</surname><given-names>N</given-names></name><name><surname>Hurst</surname><given-names>V</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Avey</surname><given-names>MT</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Howells</surname><given-names>DW</given-names></name><name><surname>Karp</surname><given-names>NA</given-names></name><name><surname>Lazic</surname><given-names>SE</given-names></name><name><surname>Lidster</surname><given-names>K</given-names></name><name><surname>MacCallum</surname><given-names>CJ</given-names></name><name><surname>Macleod</surname><given-names>M</given-names></name><name><surname>Pearl</surname><given-names>EJ</given-names></name><name><surname>Petersen</surname><given-names>OH</given-names></name><name><surname>Rawle</surname><given-names>F</given-names></name><name><surname>Reynolds</surname><given-names>P</given-names></name><name><surname>Rooney</surname><given-names>K</given-names></name><name><surname>Sena</surname><given-names>ES</given-names></name><name><surname>Silberberg</surname><given-names>SD</given-names></name><name><surname>Steckler</surname><given-names>T</given-names></name><name><surname>Würbel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>40</volume><fpage>1769</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1177/0271678X20943823</pub-id><pub-id pub-id-type="pmid">32663096</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>JB</given-names></name><name><surname>Janelidze</surname><given-names>S</given-names></name><name><surname>Strandberg</surname><given-names>O</given-names></name><name><surname>Whelan</surname><given-names>CD</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Palmqvist</surname><given-names>S</given-names></name><name><surname>Stomrud</surname><given-names>E</given-names></name><name><surname>Mattsson-Carlgren</surname><given-names>N</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology</article-title><source>Nature Aging</source><volume>2</volume><fpage>1138</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00310-z</pub-id><pub-id pub-id-type="pmid">37118533</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podcasy</surname><given-names>JL</given-names></name><name><surname>Epperson</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Considering sex and gender in Alzheimer disease and other dementias</article-title><source>Dialogues in Clinical Neuroscience</source><volume>18</volume><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.31887/DCNS.2016.18.4/cepperson</pub-id><pub-id pub-id-type="pmid">28179815</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podleśny-Drabiniok</surname><given-names>A</given-names></name><name><surname>Marcora</surname><given-names>E</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Microglial phagocytosis: A disease-associated process emerging from Alzheimer’s disease genetics</article-title><source>Trends in Neurosciences</source><volume>43</volume><fpage>965</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2020.10.002</pub-id><pub-id pub-id-type="pmid">33127097</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>AS</given-names></name><name><surname>Butler</surname><given-names>CA</given-names></name><name><surname>Allendorf</surname><given-names>DH</given-names></name><name><surname>Piers</surname><given-names>TM</given-names></name><name><surname>Mallach</surname><given-names>A</given-names></name><name><surname>Roewe</surname><given-names>J</given-names></name><name><surname>Reinhardt</surname><given-names>P</given-names></name><name><surname>Cinti</surname><given-names>A</given-names></name><name><surname>Redaelli</surname><given-names>L</given-names></name><name><surname>Boudesco</surname><given-names>C</given-names></name><name><surname>Pradier</surname><given-names>L</given-names></name><name><surname>Pocock</surname><given-names>JM</given-names></name><name><surname>Thornton</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Alzheimer’s disease-associated R47H TREM2 increases, but wild-type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss</article-title><source>Glia</source><volume>71</volume><fpage>974</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1002/glia.24318</pub-id><pub-id pub-id-type="pmid">36480007</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rönnbäck</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Dillner</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Lilius</surname><given-names>L</given-names></name><name><surname>Näslund</surname><given-names>J</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model</article-title><source>Neurobiology of Aging</source><volume>32</volume><fpage>280</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.02.021</pub-id><pub-id pub-id-type="pmid">19329229</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Matsuba</surname><given-names>Y</given-names></name><name><surname>Mihira</surname><given-names>N</given-names></name><name><surname>Takano</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Itohara</surname><given-names>S</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Saido</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Single App knock-in mouse models of Alzheimer’s disease</article-title><source>Nature Neuroscience</source><volume>17</volume><fpage>661</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1038/nn.3697</pub-id><pub-id pub-id-type="pmid">24728269</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala Frigerio</surname><given-names>C</given-names></name><name><surname>Wolfs</surname><given-names>L</given-names></name><name><surname>Fattorelli</surname><given-names>N</given-names></name><name><surname>Thrupp</surname><given-names>N</given-names></name><name><surname>Voytyuk</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>I</given-names></name><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>WT</given-names></name><name><surname>Woodbury</surname><given-names>ME</given-names></name><name><surname>Srivastava</surname><given-names>G</given-names></name><name><surname>Möller</surname><given-names>T</given-names></name><name><surname>Hudry</surname><given-names>E</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Saido</surname><given-names>T</given-names></name><name><surname>Karran</surname><given-names>E</given-names></name><name><surname>Hyman</surname><given-names>B</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Fiers</surname><given-names>M</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The major risk factors for Alzheimer’s disease: Age, sex, and genes modulate the microglia response to Aβ plaques</article-title><source>Cell Reports</source><volume>27</volume><fpage>1293</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.03.099</pub-id><pub-id pub-id-type="pmid">31018141</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirmer</surname><given-names>L</given-names></name><name><surname>Velmeshev</surname><given-names>D</given-names></name><name><surname>Holmqvist</surname><given-names>S</given-names></name><name><surname>Kaufmann</surname><given-names>M</given-names></name><name><surname>Werneburg</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name><name><surname>Vistnes</surname><given-names>S</given-names></name><name><surname>Stockley</surname><given-names>JH</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Steindel</surname><given-names>M</given-names></name><name><surname>Tung</surname><given-names>B</given-names></name><name><surname>Goyal</surname><given-names>N</given-names></name><name><surname>Bhaduri</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>S</given-names></name><name><surname>Engler</surname><given-names>JB</given-names></name><name><surname>Bayraktar</surname><given-names>OA</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>R</given-names></name><name><surname>Schafer</surname><given-names>DP</given-names></name><name><surname>Friese</surname><given-names>MA</given-names></name><name><surname>Shiow</surname><given-names>LR</given-names></name><name><surname>Kriegstein</surname><given-names>AR</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Neuronal vulnerability and multilineage diversity in multiple sclerosis</article-title><source>Nature</source><volume>573</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1404-z</pub-id><pub-id pub-id-type="pmid">31316211</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spangenberg</surname><given-names>E</given-names></name><name><surname>Severson</surname><given-names>PL</given-names></name><name><surname>Hohsfield</surname><given-names>LA</given-names></name><name><surname>Crapser</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Burton</surname><given-names>EA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Spevak</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Phan</surname><given-names>NY</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Rymar</surname><given-names>A</given-names></name><name><surname>Tsang</surname><given-names>G</given-names></name><name><surname>Walters</surname><given-names>J</given-names></name><name><surname>Nespi</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Broome</surname><given-names>S</given-names></name><name><surname>Ibrahim</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Green</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3758</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11674-z</pub-id><pub-id pub-id-type="pmid">31434879</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>K</given-names></name><name><surname>Friedman</surname><given-names>BA</given-names></name><name><surname>Etxeberria</surname><given-names>A</given-names></name><name><surname>Huntley</surname><given-names>MA</given-names></name><name><surname>van der Brug</surname><given-names>MP</given-names></name><name><surname>Foreman</surname><given-names>O</given-names></name><name><surname>Paw</surname><given-names>JS</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Serrano</surname><given-names>GE</given-names></name><name><surname>Hansen</surname><given-names>DV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alzheimer’s patient microglia exhibit enhanced aging and unique transcriptional activation</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107843</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107843</pub-id><pub-id pub-id-type="pmid">32610143</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>H-C</given-names></name><name><surname>Wang</surname><given-names>BY</given-names></name><name><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer’s disease</article-title><source>Acta Neuropathologica Communications</source><volume>2</volume><elocation-id>146</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-014-0146-2</pub-id><pub-id pub-id-type="pmid">25330988</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Rochford</surname><given-names>CDP</given-names></name><name><surname>Neumann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>647</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1084/jem.20041611</pub-id><pub-id pub-id-type="pmid">15728241</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tejera</surname><given-names>D</given-names></name><name><surname>Mercan</surname><given-names>D</given-names></name><name><surname>Sanchez-Caro</surname><given-names>JM</given-names></name><name><surname>Hanan</surname><given-names>M</given-names></name><name><surname>Greenberg</surname><given-names>D</given-names></name><name><surname>Soreq</surname><given-names>H</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Golenbock</surname><given-names>D</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome</article-title><source>The EMBO Journal</source><volume>38</volume><elocation-id>e101064</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2018101064</pub-id><pub-id pub-id-type="pmid">31359456</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turk</surname><given-names>V</given-names></name><name><surname>Stoka</surname><given-names>V</given-names></name><name><surname>Vasiljeva</surname><given-names>O</given-names></name><name><surname>Renko</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Turk</surname><given-names>B</given-names></name><name><surname>Turk</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cysteine cathepsins: from structure, function and regulation to new frontiers</article-title><source>Biochimica et Biophysica Acta</source><volume>1824</volume><fpage>68</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2011.10.002</pub-id><pub-id pub-id-type="pmid">22024571</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzioras</surname><given-names>M</given-names></name><name><surname>Daniels</surname><given-names>MJD</given-names></name><name><surname>Davies</surname><given-names>C</given-names></name><name><surname>Baxter</surname><given-names>P</given-names></name><name><surname>King</surname><given-names>D</given-names></name><name><surname>McKay</surname><given-names>S</given-names></name><name><surname>Varga</surname><given-names>B</given-names></name><name><surname>Popovic</surname><given-names>K</given-names></name><name><surname>Hernandez</surname><given-names>M</given-names></name><name><surname>Stevenson</surname><given-names>AJ</given-names></name><name><surname>Barrington</surname><given-names>J</given-names></name><name><surname>Drinkwater</surname><given-names>E</given-names></name><name><surname>Borella</surname><given-names>J</given-names></name><name><surname>Holloway</surname><given-names>RK</given-names></name><name><surname>Tulloch</surname><given-names>J</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name><name><surname>Latta</surname><given-names>C</given-names></name><name><surname>Kandasamy</surname><given-names>J</given-names></name><name><surname>Sokol</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Miron</surname><given-names>VE</given-names></name><name><surname>Káradóttir</surname><given-names>RT</given-names></name><name><surname>Hardingham</surname><given-names>GE</given-names></name><name><surname>Henstridge</surname><given-names>CM</given-names></name><name><surname>Brennan</surname><given-names>PM</given-names></name><name><surname>McColl</surname><given-names>BW</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Human astrocytes and microglia show augmented ingestion of synapses in Alzheimer’s disease via MFG-E8</article-title><source>Cell Reports. Medicine</source><volume>4</volume><elocation-id>101175</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101175</pub-id><pub-id pub-id-type="pmid">37652017</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzioras</surname><given-names>M</given-names></name><name><surname>McGeachan</surname><given-names>RI</given-names></name><name><surname>Durrant</surname><given-names>CS</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Synaptic degeneration in Alzheimer disease</article-title><source>Nature Reviews. Neurology</source><volume>19</volume><fpage>19</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/s41582-022-00749-z</pub-id><pub-id pub-id-type="pmid">36513730</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Hove</surname><given-names>H</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Scheyltjens</surname><given-names>I</given-names></name><name><surname>De Vlaminck</surname><given-names>K</given-names></name><name><surname>Pombo Antunes</surname><given-names>AR</given-names></name><name><surname>De Prijck</surname><given-names>S</given-names></name><name><surname>Vandamme</surname><given-names>N</given-names></name><name><surname>De Schepper</surname><given-names>S</given-names></name><name><surname>Van Isterdael</surname><given-names>G</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Aerts</surname><given-names>J</given-names></name><name><surname>Berx</surname><given-names>G</given-names></name><name><surname>Boeckxstaens</surname><given-names>GE</given-names></name><name><surname>Vandenbroucke</surname><given-names>RE</given-names></name><name><surname>Vereecke</surname><given-names>L</given-names></name><name><surname>Moechars</surname><given-names>D</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name><name><surname>Van Ginderachter</surname><given-names>JA</given-names></name><name><surname>Saeys</surname><given-names>Y</given-names></name><name><surname>Movahedi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>1021</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0393-4</pub-id><pub-id pub-id-type="pmid">31061494</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>A</given-names></name><name><surname>Gelosa</surname><given-names>P</given-names></name><name><surname>Castiglioni</surname><given-names>L</given-names></name><name><surname>Cimino</surname><given-names>M</given-names></name><name><surname>Rizzi</surname><given-names>N</given-names></name><name><surname>Pepe</surname><given-names>G</given-names></name><name><surname>Lolli</surname><given-names>F</given-names></name><name><surname>Marcello</surname><given-names>E</given-names></name><name><surname>Sironi</surname><given-names>L</given-names></name><name><surname>Vegeto</surname><given-names>E</given-names></name><name><surname>Maggi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sex-specific features of microglia from adult mice</article-title><source>Cell Reports</source><volume>23</volume><fpage>3501</fpage><lpage>3511</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.048</pub-id><pub-id pub-id-type="pmid">29924994</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>A</given-names></name><name><surname>Della Torre</surname><given-names>S</given-names></name><name><surname>Maggi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sexual differentiation of microglia</article-title><source>Frontiers in Neuroendocrinology</source><volume>52</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.yfrne.2018.11.003</pub-id><pub-id pub-id-type="pmid">30481522</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Mallinson</surname><given-names>K</given-names></name><name><surname>Ulrich</surname><given-names>JD</given-names></name><name><surname>Young</surname><given-names>KL</given-names></name><name><surname>Robinette</surname><given-names>ML</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Krishnan</surname><given-names>GM</given-names></name><name><surname>Sudhakar</surname><given-names>S</given-names></name><name><surname>Zinselmeyer</surname><given-names>BH</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model</article-title><source>Cell</source><volume>160</volume><fpage>1061</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.01.049</pub-id><pub-id pub-id-type="pmid">25728668</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>FL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tom</surname><given-names>I</given-names></name><name><surname>Gonzalez</surname><given-names>LC</given-names></name><name><surname>Sheng</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia</article-title><source>Neuron</source><volume>91</volume><fpage>328</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.06.015</pub-id><pub-id pub-id-type="pmid">27477018</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Meilandt</surname><given-names>WJ</given-names></name><name><surname>Dejanovic</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Bohlen</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Sheng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer’s disease</article-title><source>Nature Neuroscience</source><volume>26</volume><fpage>430</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1038/s41593-022-01251-x</pub-id><pub-id pub-id-type="pmid">36732642</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Sloan</surname><given-names>SA</given-names></name><name><surname>Bennett</surname><given-names>ML</given-names></name><name><surname>Scholze</surname><given-names>AR</given-names></name><name><surname>O’Keeffe</surname><given-names>S</given-names></name><name><surname>Phatnani</surname><given-names>HP</given-names></name><name><surname>Guarnieri</surname><given-names>P</given-names></name><name><surname>Caneda</surname><given-names>C</given-names></name><name><surname>Ruderisch</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Liddelow</surname><given-names>SA</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Daneman</surname><given-names>R</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Wu</surname><given-names>JQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex</article-title><source>The Journal of Neuroscience</source><volume>34</volume><fpage>11929</fpage><lpage>11947</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1860-14.2014</pub-id><pub-id pub-id-type="pmid">25186741</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sloan</surname><given-names>SA</given-names></name><name><surname>Clarke</surname><given-names>LE</given-names></name><name><surname>Caneda</surname><given-names>C</given-names></name><name><surname>Plaza</surname><given-names>CA</given-names></name><name><surname>Blumenthal</surname><given-names>PD</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Steinberg</surname><given-names>GK</given-names></name><name><surname>Edwards</surname><given-names>MSB</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Duncan</surname><given-names>JA</given-names></name><name><surname>Cheshier</surname><given-names>SH</given-names></name><name><surname>Shuer</surname><given-names>LM</given-names></name><name><surname>Chang</surname><given-names>EF</given-names></name><name><surname>Grant</surname><given-names>GA</given-names></name><name><surname>Gephart</surname><given-names>MGH</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse</article-title><source>Neuron</source><volume>89</volume><fpage>37</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.11.013</pub-id><pub-id pub-id-type="pmid">26687838</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>WM</given-names></name><name><surname>Andhey</surname><given-names>PS</given-names></name><name><surname>Swain</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>KR</given-names></name><name><surname>Poliani</surname><given-names>PL</given-names></name><name><surname>Cominelli</surname><given-names>M</given-names></name><name><surname>Grover</surname><given-names>S</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Ulland</surname><given-names>TK</given-names></name><name><surname>Zaitsev</surname><given-names>K</given-names></name><name><surname>Miyashita</surname><given-names>A</given-names></name><name><surname>Ikeuchi</surname><given-names>T</given-names></name><name><surname>Sainouchi</surname><given-names>M</given-names></name><name><surname>Kakita</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Nichols</surname><given-names>MR</given-names></name><name><surname>Beausoleil</surname><given-names>SA</given-names></name><name><surname>Ulrich</surname><given-names>JD</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease</article-title><source>Nature Medicine</source><volume>26</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0695-9</pub-id><pub-id pub-id-type="pmid">31932797</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85279.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>Beth</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.11.18.516922" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.18.516922"/></front-stub><body><p>This study presents a valuable finding on the function of the gene Cst7 in sex-divergent pathological changes in microglia in a mouse model of amyloid-driven Alzheimer's disease. The evidence supporting the claims of the authors is solid, although the study would be further strengthened by validation of some of the key differentially expressed genes identified in RNA-sequencing experiments. Overall, this study offers new insight into the functional role of CST7 that is upregulated in a subset of disease-associated microglia in AD models and the human brain that will be of interest to neuroimmunologists and neuroscientists working on microglia in health and disease.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85279.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Stevens</surname><given-names>Beth</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cheadle</surname><given-names>Lucas M</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02qz8b764</institution-id><institution>Cold Spring Harbor Laboratory</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.18.516922">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.11.18.516922v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Cystatin F (Cst7) drives sex-dependent changes in microglia in an amyloid-driven model of Alzheimer's Disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our board of Reviewing Editors, and the evaluation has been overseen by and Carla Rothlin as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Lucas M Cheadle (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The authors should validate several of the main gene expression /DE changes they report by RNA-sequencing, using an approach such as smFISH. Validation of RNA-sequencing experiments are important for confirming the identified changes in intact tissue and would allow the authors to identify which cells are expressing which genes.</p><p>Also, it is not clear if the authors performed the tissue dissociation in such a way as to avoid the aberrant activation of cells in the tissue. If not, then it is not possible to distinguish which gene expression changes occurred in vivo versus following dissection.</p><p>2. Data that supports the selectivity of Cst7 expression in microglia in AD is limited. Please address this claim by showing data from analysis of available datasets including other cell types. Given the authors use a global KO, it is important to demonstrate that Cst7-/- is in fact only affecting microglia in these experiments and comment on limitations and alternative interpretations of data in the text.</p><p>3. Addition of an earlier time point would allow the authors to assess whether Cst7 may play a role prior to late-stage disease states. For example, if the authors repeated a subset of their experiments at a 3- or 6-month time point, it would help determine whether Cst7 drives disease progression or is simply upregulated as a consequence.</p><p>4. If the central argument is that CST7 in females decreases phagocytosis and in males increases microglia activation, are there changes in amyloid plaque burden or structure in the APPNL-G-F /CST 7 KO mice compared to APPNL-G-F/CST7 WT that reflect these changes? Please address. If not, how does this affect the functional interpretation of differential expression observed in phagocytic/reactive microglia genes? Please address.</p><p>5. It is important to include a separate analysis of WT vs Cst7-/- microglia to interpret findings and address whether the effects observed in APPKI/Cst7-/- are disease-dependent effects of Cst7.</p><p>6. Data in 1B needs quantification.</p><p>7. There appears to be an error in Figure 2-S3A, the APPNL-G-F/CST7 WT mice are labeled as red, should they not be blue?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>– Please include more discussion of the role of CST7 in AD in general and its differential role in males vs females for context and background.</p><p>– There appears to be an error in Figure2-S3A, the APPNL-G-F/CST7 WT mice are labeled as red, should they not be blue?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>– Figure 1: Data from Guillot-Sestier vs Sala-Frigerio shows different effect of sex. I wondered if it would be worth sub-setting DAMs from Sala-Frigerio, and look specifically for sex-dependent differences in that population. It would add value to expand that analysis to other genes, ideally the DAM signature, to demonstrate whether the sexual dimorphism is specific for Cst7 or rather relates to a wider effect at cell phenotype level. Data in 1B needs quantification as otherwise is just an observation.</p><p>– The selectivity of Cst7 expression in microglia in AD is based on a single reference, and I would recommend expanding this claim by showing data from analysis of available datasets including other cell types. It is important, in my opinion, to demonstrate that Cst7-/- is in fact only affecting microglia.</p><p>– Lack of inclusion of WT Cst7-/- mice is problematic. Statistically, the study is unbalanced and any effects observed in APPKI/Cst7-/- cannot be categorically interpreted as disease-dependent effects of Cst7. I would strongly recommend including a separate transcriptomic analysis of WT vs Cst7-/- microglia.</p><p>– As designed, it is very difficult to disentangle the direct sex-specific effects from the age-related effects driven by sex, when it comes to Cst7-regulated genes or processes. We know female microglia age more rapidly into APP pathology, so the Cst7 effects reported here could be connected to the specific age of female/male microglia. My suggestion would have been to explore a different age, additional to 12 months, in order to truly ascertain whether Cst7 is sexually dimorphic or just part of a wider change, related to age, that affects females differentially.</p><p>– My comment re behaviour, from the previous section, is largely aspirational. My only hope is that the authors did perform some studies but preferred not to include those here, and that I can now plea for them to be reported. The disconnection between amyloid pathology and cognitive performance in APP models in sometimes astonishing, and it is a problem of the field not being able to see the whole picture. Ultimately, the data reported in this article would not truly be able to answer the relatively simple question of Is the disease better or worse after Cst7-/-?</p><p>– A final suggestion would be for the authors to integrate their thinking about how, molecularly, Cst7 is affecting the reported mechanisms in microglia. The reported results are largely descriptive and miss a bit the trick of describing a mechanism. The discussion covers this, to some extent, discussing potential roles of cathepsins. I understand it's often tricky to have a complete view of a mechanism, but having some ideas would help the reader.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>One recommendation that could increase the quality and mechanistic insights in the study would be to ensure that RNA-sequencing data are acquired following protocols developed to limit the aberrant activation of microglia through tissue dissociation (see Marsh et al., Nature Neuroscience, 2022). In combination, the authors should validate several of the gene expression changes they report by RNA-sequencing using an approach such as FISH. Cell-type-resolution will be important to validate whether these changes are real, so approaches with spatial resolution are better than assays such as qPCR.</p><p>It would also be helpful for the authors to plot statistical differences for a given parameter between sexes. Even if these changes are insignificant, it would be helpful to show that on the graphs. I would also suggest that, if these changes are not significant, the authors provide a discussion of why that might be and how that might impact their conclusions.</p><p>Finally, it would be very helpful to add to the study an earlier time point that could allow the authors to assess whether Cst7 may play a role in the disease prior to late-stage disease states. For example, if the authors repeated a subset of their experiments at a 3- or 6-month time point, it would contribute substantially to their ability to determine whether Cst7 drives disease progression or is simply upregulated as a result.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85279.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The authors should validate several of the main gene expression /DE changes they report by RNA-sequencing, using an approach such as smFISH. Validation of RNA-sequencing experiments are important for confirming the identified changes in intact tissue and would allow the authors to identify which cells are expressing which genes.</p></disp-quote><p>We focussed attention on <italic>Lilrb4</italic> given its inclusion in Figure 2E showing sex-dependent patterns altered in disease and its relevance to myeloid cell activation. Using combined single-molecule detection FISH (RNAscope) and immunofluorescence we observed that <italic>Lilrb4</italic> is expressed in plaque-associated IBA1+ cells (Figure 2. – figure supplement 3). Quantification of IBA1+<italic>Lilrb4</italic>+ showed the equivalent pattern to our microglial RNAseq data thus confirming findings <italic>in situ</italic>. We also attempted a similar approach with probes for <italic>Il1b</italic>, another gene we showed has sex-dependent patterns in the disease condition, however we could not get probe labelling to work, including in positive control samples.</p><disp-quote content-type="editor-comment"><p>Also, it is not clear if the authors performed the tissue dissociation in such a way as to avoid the aberrant activation of cells in the tissue. If not, then it is not possible to distinguish which gene expression changes occurred in vivo versus following dissection.</p></disp-quote><p>We took standard precautions to minimise the risk of aberrant ex vivo cell activation, including maintaining cells on ice during non-enzyme steps of the procedure and carrying out preps in small batches to minimise time taken from removal of brain to purification of microglial RNA. Importantly, we also validated key expression data by <italic>in situ</italic> methods as above (Figure 2. – figure supplement 3) thus eliminating dissection-induced effects. Additionally, when performing qPCR on microglia from non-disease mice to test the disease-specific role of <italic>Cst7</italic>-dependent gene regulation we did not observe the same gene changes (Figure 2. – figure supplement 4) which, if such changes were dependent on tissue dissociation, we would expect to observe in naive or disease animals. We utilised the resources provided by Marsh et al. 2022 to search for overlap between enzyme-induced genes and our DEG lists from our key comparisons. We found the enzyme-induced gene set had very minimal overlap with any of our comparisons with overlap of only 4 genes between enzyme-induced genes and <italic>Cst7</italic>-dependent genes in males and no overlap between enzyme-induced genes and <italic>Cst7</italic>-dependent genes in females (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). We would further point out that the disease-induced microglial RNAseq profile in the <italic>App<sup>NL-G-F</sup> Cst7<sup>+/+</sup></italic> (i.e. disease WT) condition mirrors those observed previously by multiple methods including in situ profiling (Zeng et al. 2023 – PMID: 36732642) and RiboTag approaches (Kang et al. 2018 – PMID: 30082275). With a combination of these approaches, we believe it extremely unlikely that the gene changes we observe our due to artifacts induced by dissection.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85279-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2. Data that supports the selectivity of Cst7 expression in microglia in AD is limited. Please address this claim by showing data from analysis of available datasets including other cell types. Given the authors use a global KO, it is important to demonstrate that Cst7-/- is in fact only affecting microglia in these experiments and comment on limitations and alternative interpretations of data in the text.</p></disp-quote><p>We agree this is an important point and now provide multiple sources of evidence that <italic>Cst7</italic> is almost exclusively derived from microglia (and likely only in disease conditions). <italic>Cst7</italic> is expressed only in the microglia/macrophage sample from bulk RNAseq on sorted CNS cell types (Zhang et al., 2014 – PMID: 25186741/BrainRNASeq) and in scRNAseq brain cell atlases (Saunders et al., 2018 – PMID: 30096299/DropViz). All these sources indicate expression is negligible in steady-state as we observe in the current study, including by RNAseq (Figure 2. – figure supplement 3) and <italic>Cst7</italic> FISH (Figure 1. – figure supplement 1). Therefore, relative cell expression of <italic>Cst7</italic> in steady-state must be interpreted with this in mind but nonetheless if it is expressed it appears restricted to brain macrophages and further to microglia (e.g. no co-expression with border macrophage marker gene expressing cells in Saunders et al., 2018 – PMID: 30096299/DropViz). Our FISH data show <italic>Cst7</italic> exclusively expressed in the <italic>App<sup>NL-G-F</sup></italic> condition and localised only to plaque-associated IBA1+ cells (without perivascular location) (Figure 1B-E and Figure 1. – figure supplement 1). An independent scRNAseq dataset of CNS macrophage populations also shows above-background expression in reactive (DAM) microglia only (Van Hove et al., 2019 – PMID: 31061494) and a recent spatial transcriptomics analysis of TauPS2APP mice shops the high <italic>Cst7</italic> expression restricted to peri-plaque microglia (Zeng et al., 2023 – PMID: 36732642) (Figure 1. – figure supplement 1). We also highlight that <italic>Cst7</italic> is expressed in reactive microglia but not monocyte-derived macrophages in brain pathology where these cells co-locate (Patir et al., 2023, BioRXiv, Figure 8). We have updated figures with the additional data from independent datasets and further comment on the weight of evidence indicating effects of <italic>Cst7</italic> deletion are likely explained by a microglial mechanism.</p><disp-quote content-type="editor-comment"><p>3. Addition of an earlier time point would allow the authors to assess whether Cst7 may play a role prior to late-stage disease states. For example, if the authors repeated a subset of their experiments at a 3- or 6-month time point, it would help determine whether Cst7 drives disease progression or is simply upregulated as a consequence.</p></disp-quote><p>We believe this point relates to a comment from reviewer 3 to whom we also reply below. Our data strongly support a mechanism whereby early disease drives <italic>Cst7</italic> expression which then exerts disease-influencing effects on further progression as shown by the effects we see of <italic>Cst7</italic> deletion on microglial phenotype and disease pathology. We expect this is reflective more broadly of how microglia may be involved in AD-like progression i.e. early trigger(s) provoke microglial reactivity and thereafter modulators of this microglial reaction then influence subsequent disease progression. We accept that exploring additional timepoints both before and after the 12-month point we selected could potentially provide additional insight; unfortunately, we do not have the resources available to conduct additional timepoint studies. Nonetheless, we believe the existing conclusions would not likely be materially altered. <italic>Cst7</italic> expression is low until 6-12 months (see data from Sala-Frigerio et al.) making a 12 month timepoint a rational age to evaluate both the impact on cell phenotype/functions and disease pathology. At this age, cells inducing <italic>Cst7</italic> from a negligible baseline (see comments above) have had the temporal window to affect disease pathology, as we find in the current study in a sex-dependent manner. Overall, we believe the fact that genetic deletion of a single (microglia-specific) gene has an effect on microglial phenotype and disease pathology is strong evidence that the effects observed are due to the gene itself and not simply a result of upregulation as a consequence.</p><disp-quote content-type="editor-comment"><p>4. If the central argument is that CST7 in females decreases phagocytosis and in males increases microglia activation, are there changes in amyloid plaque burden or structure in the APPNL-G-F /CST 7 KO mice compared to APPNL-G-F/CST7 WT that reflect these changes? Please address. If not, how does this affect the functional interpretation of differential expression observed in phagocytic/reactive microglia genes? Please address.</p></disp-quote><p>This comment relates to a query from Reviewer #1 – we emphasise the data already presented in Figure 6 and Figure 6 – figure supplement 2 showing altered Aβ burden (6E10 staining) and plaque count (MeX04) but no change in plaque area. Regarding the functional interpretation of <italic>Cst7</italic>-dependent gene changes in microglia beyond the endolysosomal function we present in figures 3-5, we have included additional data using simple immunohistochemistry, as suggested by the reviewer, to assess synapse abundance. We show loss of Sy38 coverage around plaques (Figure 6I) and a moderate but significant decrease in coverage between <italic>App<sup>NL-G-F</sup>/Cst7<sup>-/-</sup></italic> vs <italic>App<sup>NL-G-F</sup></italic> brains only in females (Figure 6J). This reflects the effect observed with plaque coverage whereby we observe increased burden in <italic>App<sup>NL-G-F</sup>/Cst7<sup>-/-</sup></italic> vs <italic>App<sup>NL-G-F</sup></italic> females but not males (Figure 6B-F) suggesting the increased plaque burden in <italic>Cst7<sup>-/-</sup></italic> female mice may lead to increased synapse loss. We would also emphasise that altered expression of phagolysosomal genes could affect disease in ways beyond interactions with amyloid and synapses.</p><disp-quote content-type="editor-comment"><p>5. It is important to include a separate analysis of WT vs Cst7-/- microglia to interpret findings and address whether the effects observed in APPKI/Cst7-/- are disease-dependent effects of Cst7.</p></disp-quote><p>We agree this is an important element to the interpretation of the manuscript. We have now compared expression of genes for which we found sex/disease-dependent differential expression of <italic>Cst7</italic> in our original analysis (e.g. <italic>Il1b, Lilrb4a</italic>) in non-disease microglia isolated from WT and <italic>Cst7</italic>-/- mice and this shows no significant effect of <italic>Cst7</italic> deletion on either gene (Figure 2. – figure supplement 3). Moreover, the disease-specific expression pattern described above and in Figure 1. – figure supplement 1 and our own data (Figure 2 – figure supplement 3) with <italic>Cst7</italic> minimally expressed at baseline and upregulated in disease supports that <italic>Cst7</italic> will mediate effects in disease but not baseline state. Consistent with this, we saw no effect of <italic>Cst7</italic> deficiency in our in multiple vitro assays using microglia derived from non-disease mice (Figure 5 – figure supplement 1-3). In contrast, assays using microglia derived from 12-month-old <italic>App<sup>NL-G-F</sup></italic> mice revealed functional effects of <italic>Cst7</italic> deficiency (Figure 5). Together, these findings emphasise a disease-dependent role for <italic>Cst7</italic>.</p><disp-quote content-type="editor-comment"><p>6. Data in 1B needs quantification.</p></disp-quote><p>We have provided quantification of our own newly-generated <italic>Cst7</italic> FISH data now presented in Figure 1. Here we show that <italic>Cst7</italic> is expressed specifically around the plaques and overlaps with IBA1+ cells.</p><disp-quote content-type="editor-comment"><p>7. There appears to be an error in Figure 2-S3A, the APPNL-G-F/CST7 WT mice are labeled as red, should they not be blue?</p></disp-quote><p>Thank you for picking this up – we have corrected the figure.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>– Please include more discussion of the role of CST7 in AD in general and its differential role in males vs females for context and background.</p></disp-quote><p>We believe we have covered this topic in the introduction (third paragraph). However, we have added recent references to the limited studies on the functional role of <italic>Cst7</italic> in AD and to the regulation of <italic>Cst7</italic> in ageing.</p><disp-quote content-type="editor-comment"><p>– There appears to be an error in Figure2-S3A, the APPNL-G-F/CST7 WT mice are labeled as red, should they not be blue?</p></disp-quote><p>We thank the reviewer for spotting this error and have rectified the labelling mistake.</p><p>We also draw attention to further revisions conducted beyond these recommendations in our point-by-point response to all comments above from Reviewer #1.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>– Figure 1: Data from Guillot-Sestier vs Sala-Frigerio shows different effect of sex. I wondered if it would be worth sub-setting DAMs from Sala-Frigerio, and look specifically for sex-dependent differences in that population. It would add value to expand that analysis to other genes, ideally the DAM signature, to demonstrate whether the sexual dimorphism is specific for Cst7 or rather relates to a wider effect at cell phenotype level. Data in 1B needs quantification as otherwise is just an observation.</p></disp-quote><p>As requested, we have sub-setted the DAMs (ARMs in this case) from Sala-Frigerio et al. and investigated sex-specific effects (Figure 1 —figure supplement 1A). Effect sizes overall are low, suggesting the main effect observed is due to the proportion of ARMs being (marginally) greater in female than male rather than the ARMs identity being different. However, we observe a number of genes more greatly expressed in the female ARM than male including <italic>Spp1</italic>, <italic>Cst7</italic>, and <italic>Gpnmb</italic> (as well as sex-chromosome genes). We have added this analysis to Figure 1A.</p><p>Regarding the data in 1B please see out comment above. Also copied here:</p><p>We have provided quantification of our own newly-generated <italic>Cst7</italic> FISH data now presented in Figure 1. Here we show that <italic>Cst7</italic> is expressed specifically around the plaques and overlaps with IBA1+ cells.</p><disp-quote content-type="editor-comment"><p>– The selectivity of Cst7 expression in microglia in AD is based on a single reference, and I would recommend expanding this claim by showing data from analysis of available datasets including other cell types. It is important, in my opinion, to demonstrate that Cst7-/- is in fact only affecting microglia.</p></disp-quote><p>Please see our response to Reviewer #1 above, repeated here:</p><p>We agree this is an important point and now provide multiple sources of evidence that <italic>Cst7</italic> is almost exclusively derived from microglia (and likely only in disease conditions). <italic>Cst7</italic> is expressed only in the microglia/macrophage sample from bulk RNAseq on sorted CNS cell types (Zhang et al. 2014 – PMID: 25186741/BrainRNASeq) and in scRNAseq brain cell atlases (Saunders et al. 2018 – PMID: 30096299/DropViz). All these sources indicate expression is negligible in steady-state as we observe in the current study, including by RNAseq (Figure 2. – figure supplement 3), <italic>Cst7</italic> FISH (Figure 1. – figure supplement 1) and qPCR on isolated microglia in culture (Figure 5B). Therefore, relative cell expression of <italic>Cst7</italic> in steady-state must be interpreted with this in mind but nonetheless if it is expressed it appears restricted to brain macrophages and further to microglia (e.g. no co-expression with border macrophage marker gene expressing cells in Saunders et al. 2018 – PMID: 30096299/DropViz). Our FISH data show <italic>Cst7</italic> exclusively expressed in the <italic>App<sup>NL-G-F</sup></italic> condition and localised only to plaque-associated IBA1+ cells (without perivascular location) (Figure 1B-E and Figure 1. – figure supplement 1). An independent scRNAseq dataset of CNS macrophage populations also shows above-background expression in reactive (DAM) microglia only (Van Hove et al. 2019 – PMID: 31061494) and a recent spatial transcriptomics analysis of TauPS2APP mice shops the high <italic>Cst7</italic> expression restricted to peri-plaque microglia (Zeng et al. 2023 – PMID: 36732642) (Figure 1. – figure supplement 1). We also highlight that <italic>Cst7</italic> is expressed in reactive microglia but not monocyte-derived macrophages in brain pathology where these cells co-locate (Patir et al. 2023, BioRXiv, Figure 8). We have updated figures with the additional data from independent datasets and further comment on the weight of evidence indicating effects of <italic>Cst7</italic> deletion are likely explained by a microglial mechanism.</p><disp-quote content-type="editor-comment"><p>– Lack of inclusion of WT Cst7-/- mice is problematic. Statistically, the study is unbalanced and any effects observed in APPKI/Cst7-/- cannot be categorically interpreted as disease-dependent effects of Cst7. I would strongly recommend including a separate transcriptomic analysis of WT vs Cst7-/- microglia.</p></disp-quote><p>We agree this is an important element to the interpretation of the manuscript. We have now compared expression of genes for which we found sex/disease-dependent differential expression of <italic>Cst7</italic> in our original analysis (e.g. <italic>Il1b, Lilrb4a</italic>, <italic>Cst7</italic>) in non-disease microglia isolated from WT and <italic>Cst7</italic>-/- mice and this shows no significant effect of <italic>Cst7</italic> deletion on any gene (Figure 2. – figure supplement 3). Moreover, the disease-specific expression pattern described above and in Figure 1. – figure supplement 1 (with <italic>Cst7</italic> minimally expressed at baseline and upregulated in disease) supports that <italic>Cst7</italic> will mediate effects in disease but not baseline state. Consistent with this, we saw no effect of <italic>Cst7</italic> deficiency in our in multiple vitro assays using microglia derived from non-disease mice (Figure 5 – figure supplement 1-3). In contrast, assays using microglia derived from 12-month old <italic>App<sup>NL-G-F</sup></italic> mice revealed functional effects of <italic>Cst7</italic> deficiency (Figure 5). Together, these findings emphasise a disease-restricted role for <italic>Cst7</italic>.</p><disp-quote content-type="editor-comment"><p>– As designed, it is very difficult to disentangle the direct sex-specific effects from the age-related effects driven by sex, when it comes to Cst7-regulated genes or processes. We know female microglia age more rapidly into APP pathology, so the Cst7 effects reported here could be connected to the specific age of female/male microglia. My suggestion would have been to explore a different age, additional to 12 months, in order to truly ascertain whether Cst7 is sexually dimorphic or just part of a wider change, related to age, that affects females differentially.</p></disp-quote><p>We agree this is a challenging element to disentangle however would reiterate that whether <italic>Cst7</italic> expression in disease is sexually dimorphic is a separate question from whether deleting <italic>Cst7</italic> has a sexually dimorphic impact on microglial phenotype and other disease features – indeed, that <italic>Cst7</italic> itself seems to not be expressed significantly differently between male and female <italic>App<sup>NL-G-F</sup></italic> microglia in our data , along with other data, favours that the impact of deleting <italic>Cst7</italic> is a direct/intrinsic sex effect and not simply a sex effect caused by sex-related stepped ageing trajectories.</p><p>Our response above to Reviewer #1 is repeated here for consistency:</p><p>This is an interesting question and while we acknowledge that empirically addressing with a later timepoint could add insight, we believe it would actually need multiple closely-spaced timepoints as choosing what single later timepoint would be optimal is difficult to judge (and likely not possible at all) for reasons below. We also believe data already published combined with our observations show it is most-likely a cell-intrinsic effect that explains our sex-specific differences.</p><p>First, we emphasize the acceleration of the microglial phenotype in female <italic>App<sup>NL-G-F</sup></italic> mice previously published is fairly subtle and relative rather than absolute e.g. the DAM/ARM microglia state represents ~50% of all microglia in male and ~55% of all microglia in females at 12 months old therefore both sexes have similarly abundant microglia in the state that most highly express <italic>Cst7.</italic> Indeed, after the age at which DAM/ARM state microglia appear in appreciable numbers (~ 6 months), both females and males both have an abundance of them. It is important to note that a 12-month male is far more “progressed” than a 6-month female hence the stepped age effect is temporally short.</p><p>Second, <italic>Cst7</italic> deletion in the <italic>App<sup>NL-G-F</sup></italic> mice condition caused qualitative differences affecting distinct genes and/or overlapping genes moving in different directions between female and male mice (Figure 2, Figure 2-figure supplement 3) – if a stepped age effect explained sex differences from <italic>Cst7</italic> deletion, given that it could only be stepped by a very short timeframe (several weeks maximum) from reasoning above, we would expect to see similar qualitative changes but of different magnitude in female and male mice arising from <italic>Cst7</italic> deletion; this is not the pattern we see.</p><p>Third, beyond 12 months old, regression from ARM/DAM actually occurs, again making it unlikely males would “catch up” with females to show the same profile from <italic>Cst7</italic> deletion but just at an older age – practically, this also complicates choosing a single later timepoint (and age-related systemic morbidity emerges as a potential confounder as well).</p><p>In summary, while the acceleration of the DAM signature in female microglia offers an intriguing possible explanation to our observation of sexual dimorphism in response to deletion of one of the key genes in this signature, we believe it more likely that intrinsic effects are responsible for the <italic>Cst7</italic> deletion sex-related impact. Taking the alternative perspective, even if a stepped age effect in the underlying progression of the model could explain our findings, this would need multiple timepoints with short gaps between (e.g. monthly at 12, 13, 14, 15 months old) to provide the temporal resolution to expose this pattern; we would not have the resources to conduct such a resource-intensive and lengthy study. We hope this reasoning appears logical and conscious of the importance to convey this in our manuscript we have revised the Discussion to as concisely as possible capture some key points outlined above.</p><disp-quote content-type="editor-comment"><p>– My comment re behaviour, from the previous section, is largely aspirational. My only hope is that the authors did perform some studies but preferred not to include those here, and that I can now plea for them to be reported. The disconnection between amyloid pathology and cognitive performance in APP models in sometimes astonishing, and it is a problem of the field not being able to see the whole picture. Ultimately, the data reported in this article would not truly be able to answer the relatively simple question of Is the disease better or worse after Cst7-/-?</p></disp-quote><p>We absolutely agree with the reviewer that a behavioural/cognitive readout would be desirable. We considered from the outset but there is no behavioural test we have found with significantly robust behavioural alteration in our hands using the <italic>App<sup>NL-G-F</sup></italic> model. Indeed, there is no clear consensus in the literature for a robust behavioural readout with this model (Sakakibara et al. 2019 – PMID: 30894120, Figure 4; also personal communication with researchers across two international networks we are part of). However, to help provide insight to the key question of “Is the disease better or worse after <italic>Cst7<sup>-/-</sup></italic>&quot; we have performed immunohistochemistry as suggested by Reviewer #1 and now reported in Figure 6I and J and Figure 6 – figure supplement 1. As described above, we show loss of Sy38 coverage around plaques (Figure 6I) and a modest but significant decrease in coverage between <italic>App<sup>NL-G-F</sup>/Cst7<sup>-/-</sup> vs. App<sup>NL-G-F</sup></italic> brains only in females. This reflects the effect observed with plaque coverage whereby we observe increased burden in <italic>App<sup>NL-G-F</sup>/Cst7<sup>-/-</sup></italic> vs <italic>App<sup>NL-G-F</sup></italic> females but not males (Figure 6B-F) suggesting the increased plaque burden in <italic>Cst7<sup>-/-</sup></italic> female mice may lead to increased synapse loss.</p><disp-quote content-type="editor-comment"><p>– A final suggestion would be for the authors to integrate their thinking about how, molecularly, Cst7 is affecting the reported mechanisms in microglia. The reported results are largely descriptive and miss a bit the trick of describing a mechanism. The discussion covers this, to some extent, discussing potential roles of cathepsins. I understand it's often tricky to have a complete view of a mechanism, but having some ideas would help the reader.</p></disp-quote><p>We believe we have addressed the molecular mechanisms by which <italic>Cst7</italic> deletion could lead to the effects we observe in this study in the discussion (see second paragraph). However, we have added to this to further integrate thinking on possible mechanisms involved.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>One recommendation that could increase the quality and mechanistic insights in the study would be to ensure that RNA-sequencing data are acquired following protocols developed to limit the aberrant activation of microglia through tissue dissociation (see Marsh et al., Nature Neuroscience, 2022). In combination, the authors should validate several of the gene expression changes they report by RNA-sequencing using an approach such as FISH. Cell-type-resolution will be important to validate whether these changes are real, so approaches with spatial resolution are better than assays such as qPCR.</p></disp-quote><p>Please see response above where we provide <italic>in situ</italic> data on <italic>Cst7</italic> and <italic>Lilrb4a</italic> in non-dissociated tissue to show microglial expression around plaques and mirrored patterns of expression in experimental groups as per our RNASeq data on sorted microglia.</p><disp-quote content-type="editor-comment"><p>It would also be helpful for the authors to plot statistical differences for a given parameter between sexes. Even if these changes are insignificant, it would be helpful to show that on the graphs. I would also suggest that, if these changes are not significant, the authors provide a discussion of why that might be and how that might impact their conclusions.</p></disp-quote><p>Please see response above where we comment further on the interaction effect we observe between sex and <italic>Cst7</italic> status. We have added further comment in the discussion on the manuscript and we have added the gene, sex and interaction effects from the main ANOVA onto the figures.</p><disp-quote content-type="editor-comment"><p>Finally, it would be very helpful to add to the study an earlier time point that could allow the authors to assess whether Cst7 may play a role in the disease prior to late-stage disease states. For example, if the authors repeated a subset of their experiments at a 3- or 6-month time point, it would contribute substantially to their ability to determine whether Cst7 drives disease progression or is simply upregulated as a result.</p></disp-quote><p>Please see response above where we discuss the utility of assessing <italic>Cst7</italic> at an earlier timepoint. We believe the fact that <italic>Cst7</italic> deletion affects key disease readouts such as plaque burden and synapse loss is direct evidence that <italic>Cst7</italic> is causally affecting disease progression.</p></body></sub-article></article>